<!doctype html>
<html lang="en">
  <head>
    <!-- Global site tag (gtag.js) - Google Analytics -->
    <script async src="https://www.googletagmanager.com/gtag/js?id=UA-77190356-3"></script>
    <script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());
      gtag('config', 'UA-77190356-3');
    </script>

    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    
    <link rel="stylesheet" href="https://api.mapbox.com/mapbox-gl-js/v0.53.0/mapbox-gl.css" />
    <link rel="stylesheet" href="./assets/css/libs.bundle.css" />
    <link rel="stylesheet" href="./assets/css/theme.bundle.css" />
    <link rel="stylesheet" href="./assets/css/various.css" />

    <title>Conf42: Combatting Antibiotic Resistance in UTI Treatment: Phase 3 Insights on Sulopenem vs. Ciprofloxacin</title>
    <meta name="description" content="Move at lightning speed thanks to the latest tools">

    
    <meta name="image" property="og:image" content="https://www.conf42.com/assets/headshots/https://conf42.github.io/static/headshots/Karthik%20Akinapelli_devops.png">
    <meta property="og:type" content="article"/>
    <meta property="og:title" content="Combatting Antibiotic Resistance in UTI Treatment: Phase 3 Insights on Sulopenem vs. Ciprofloxacin | Conf42"/>
    <meta property="og:description" content="Discover how we’re revolutionizing UTI treatment in the fight against antibiotic resistance! Learn about sulopenem's groundbreaking success against multi-drug resistant pathogens, offering hope where other antibiotics fail. Join us for game-changing insights into the future of infection management!"/>
    <meta property="og:url" content="https://conf42.com/DevOps_2025_Karthik_Akinapelli_antibiotic_treatment_resistance"/>
    

    <link rel="shortcut icon" href="./assets/favicon/favicon.ico" type="image/x-icon" />
    <link rel="apple-touch-icon" sizes="180x180" href="./assets/favicon/apple-touch-icon.png">
    <link rel="icon" type="image/png" sizes="32x32" href="./assets/favicon/favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="./assets/favicon/favicon-16x16.png">
    <link rel="manifest" href="./assets/favicon/site.webmanifest">

    

  <!-- Reddit Pixel -->
  <script>
  !function(w,d){if(!w.rdt){var p=w.rdt=function(){p.sendEvent?p.sendEvent.apply(p,arguments):p.callQueue.push(arguments)};p.callQueue=[];var t=d.createElement("script");t.src="https://www.redditstatic.com/ads/pixel.js",t.async=!0;var s=d.getElementsByTagName("script")[0];s.parentNode.insertBefore(t,s)}}(window,document);rdt('init','a2_e019g7ndfhrm', {"optOut":false,"useDecimalCurrencyValues":true,"aaid":"<AAID-HERE>"});rdt('track', 'PageVisit');
  </script>
  <!-- DO NOT MODIFY UNLESS TO REPLACE A USER IDENTIFIER -->
  <!-- End Reddit Pixel -->

  </head>
  <body>

    <!-- NAVBAR -->
    
    <!-- <nav class="navbar navbar-expand-lg navbar-light bg-light"> -->
    <nav class="navbar navbar-expand-lg navbar-dark bg-dark">
    
      <div class="container">
    
        <!-- Brand -->
        <a class="navbar-brand" href="./">
          <img src="./assets/conf42/conf42_logo_black_small.png" class="navbar-brand-img" alt="...">
        </a>
    
        <!-- Toggler -->
        <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarCollapse" aria-controls="navbarCollapse" aria-expanded="false" aria-label="Toggle navigation">
          <span class="navbar-toggler-icon"></span>
        </button>
    
        <!-- Collapse -->
        <div class="collapse navbar-collapse" id="navbarCollapse">
    
          <!-- Toggler -->
          <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarCollapse" aria-controls="navbarCollapse" aria-expanded="false" aria-label="Toggle navigation">
            <i class="fe fe-x"></i>
          </button>
    
          <!-- Navigation -->
          <ul class="navbar-nav ms-auto">

            <li class="nav-item dropdown">
              <a class="nav-link dropdown-toggle" id="navbarLandings" data-bs-toggle="dropdown" href="#" aria-haspopup="true" aria-expanded="false">
                Events
              </a>
              <div class="dropdown-menu dropdown-menu-xl p-0" aria-labelledby="navbarLandings">
                <div class="row gx-0">
                  <div class="col-12 col-lg-6">
                    <!-- <div class="dropdown-img-start" style="background-image: url(./assets/splash/SRE2025_Event_Splash.png);"> -->
                    <div class="dropdown-img-start">
                      <!-- Heading -->
                      <h4 class="fw-bold text-white mb-0">
                        Featured event
                      </h4>
                      <!-- Text -->
                      <p class="fs-sm text-white">
                        Site Reliability Engineering (SRE) 2025
                      </p>
                      <p class="fs-sm text-white">
                        Premiere 2025-04-17
                      </p>
                      <!-- Button -->
                      <a href="https://www.conf42.com/sre2025" class="btn btn-sm btn-white shadow-dark fonFt-size-sm">
                        Learn more
                      </a>
                    </div>
                  </div>
                  <div class="col-12 col-lg-6">
                    <div class="dropdown-body">
                      <div class="row gx-0">
                        <div class="col-12">
    
                        
                          <!-- Heading -->
                          <h6 class="dropdown-header mt-5">
                            2025
                          </h6>
                          <!-- List -->
                          
                          <a class="dropdown-item" href="https://www.conf42.com/devops2025">
                            DevOps
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/python2025">
                            Python
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/ce2025">
                            Chaos Engineering
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/cloud2025">
                            Cloud Native
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/llms2025">
                            Large Language Models (LLMs)
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/golang2025">
                            Golang
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/sre2025">
                            Site Reliability Engineering (SRE)
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/ml2025">
                            Machine Learning
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/obs2025">
                            Observability
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/quantum2025">
                            Quantum Computing
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/rustlang2025">
                            Rustlang
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/platform2025">
                            Platform Engineering
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/mlops2025">
                            MLOps
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/im2025">
                            Incident Management
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/kubenative2025">
                            Kube Native
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/js2025">
                            JavaScript
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/prompt2025">
                            Prompt Engineering
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/robotics2025">
                            Robotics
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/devsecops2025">
                            DevSecOps
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/iot2025">
                            Internet of Things (IoT)
                          </a>
                          
                        
                          <!-- Heading -->
                          <h6 class="dropdown-header mt-5">
                            2024
                          </h6>
                          <!-- List -->
                          
                          <a class="dropdown-item" href="https://www.conf42.com/devops2024">
                            DevOps
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/ce2024">
                            Chaos Engineering
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/python2024">
                            Python
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/cloud2024">
                            Cloud Native
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/llms2024">
                            Large Language Models (LLMs)
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/golang2024">
                            Golang
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/sre2024">
                            Site Reliability Engineering (SRE)
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/ml2024">
                            Machine Learning
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/obs2024">
                            Observability
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/quantum2024">
                            Quantum Computing
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/rustlang2024">
                            Rustlang
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/platform2024">
                            Platform Engineering
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/kubenative2024">
                            Kube Native
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/im2024">
                            Incident Management
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/js2024">
                            JavaScript
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/prompt2024">
                            Prompt Engineering
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/devsecops2024">
                            DevSecOps
                          </a>
                          
                          <a class="dropdown-item" href="https://www.conf42.com/iot2024">
                            Internet of Things (IoT)
                          </a>
                          
                        

                          <!-- Heading -->
                          <h6 class="dropdown-header mt-5">
                            Info
                          </h6>
                          <a class="dropdown-item" href="./code-of-conduct">
                            Code of Conduct
                          </a>
    
                        </div>
                      </div> <!-- / .row -->
                    </div>
                  </div>
                </div> <!-- / .row -->
              </div>
            </li>

            <li class="nav-item dropdown">
              <a class="nav-link dropdown-toggle" id="navbarLandings" data-bs-toggle="dropdown" href="#" aria-haspopup="true" aria-expanded="false">
                Community
              </a>
              <div class="dropdown-menu dropdown-menu-l p-0" aria-labelledby="navbarLandings">
                <div class="row gx-0">
                  <div class="col-12 col-lg-3">
                    <div class="dropdown-body">
                      <div class="row gx-0">
                        <div class="col-12">
                          <a class="dropdown-item" href="https://conf42.circle.so/">
                            <b>Community platform login</b>
                          </a>
                          <a class="dropdown-item" href="https://discord.gg/mvHyZzRGaQ" target="_blank">
                            Discord
                          </a>
                          <a class="dropdown-item" href="./hall-of-fame">
                            Hall of Fame
                          </a>
                          <a class="dropdown-item" href="./speakers">
                            Speakers
                          </a>
                          <a class="dropdown-item" href="https://www.papercall.io/events?cfps-scope=&keywords=conf42" target="_blank">
                            Become a speaker (CFPs)
                          </a>
                          <a class="dropdown-item" href="./testimonials">
                            Testimonials
                          </a>
                          <a class="dropdown-item" href="./about">
                            About the team
                          </a>
                        </div>
                      </div> <!-- / .row -->
                    </div>
                  </div>
                </div> <!-- / .row -->
              </div>
            </li>

            <li class="nav-item">
              <a class="nav-link" href="./podcast">
                Podcast
              </a>
            </li>

            <li class="nav-item">
              <a class="nav-link" href="./blog">
                Blog
              </a>
            </li>

            <li class="nav-item">
              <a class="nav-link" href="./sponsor">
                Sponsor
              </a>
            </li>
          </ul>
    
          <!-- Button -->
          <a class="navbar-btn btn btn-sm btn-primary lift ms-auto" href="#register">
            Join the community!
          </a>
    
        </div>
    
      </div>
    </nav>



<style>
.text-selected {
  background-color: #42ba96!important;
  color: white;
}
</style>
	

    <!-- WELCOME -->
    <section class="py-5 py-md-10" style="background-color: #5F3202;">

      <!-- Shape -->
      <div class="shape shape-blur-3 svg-shim text-white">
        <svg viewBox="0 0 1738 487" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M0 0h1420.92s713.43 457.505 0 485.868C707.502 514.231 0 0 0 0z" fill="url(#paint0_linear)"/><defs><linearGradient id="paint0_linear" x1="0" y1="0" x2="1049.98" y2="912.68" gradientUnits="userSpaceOnUse"><stop stop-color="currentColor" stop-opacity=".075"/><stop offset="1" stop-color="currentColor" stop-opacity="0"/></linearGradient></defs></svg>
      </div>

      <div class="container">
        <div class="row justify-content-center">
          <div class="col-12 text-center" data-aos="fade-up">

            <!-- Heading -->
            <h1 class="display-2 fw-bold text-white">
              Conf42 DevOps 2025 - Online
            </h1>

            <h2 class="text-white">
              
              <time datetime="2025-01-23">January 23 2025</time>
              
              - premiere 5PM GMT
              
              
            </h2>

            <!-- Text -->
            <p class="lead mb-0 text-white-75">
              
              <!-- Move at lightning speed thanks to the latest tools
 -->
              <script>
                const event_date = new Date("2025-01-23T17:00:00.000+00:00");
                const local_timezone = Intl.DateTimeFormat().resolvedOptions().timeZone;
                const local_date = new Date("2025-01-23T17:00:00.000+00:00");
                // const local_offset = new Date().getTimezoneOffset() / 60;
                // local_date.setHours(local_date.getHours() + local_offset);
                document.getElementById("localtime").innerHTML = local_date + " in " + local_timezone
              </script>
            </p>

            <!-- Buttons -->
            <div class="text-center mt-5">
              
              <a href="#register" class="btn btn-primary shadow lift me-1 mb-3">
                <i class="fe fe-user-check me-2"></i>
                Subscribe to watch
              </a>
              
              
              <a class="btn btn-danger lift mb-3" data-bigpicture='{"ytSrc": "2wCHiRSV_rU"}' href="#">
                <i class="fe fe-youtube me-2"></i>
                Watch this talk
              </a>
              
              
              <!-- 
              <a class="btn btn-danger lift mb-3" href="https://www.youtube.com/playlist?list=PLIuxSyKxlQrCdGhBCZtLYRLD9MT4ddCES" target="_blank">
                <i class="fe fe-youtube me-2"></i>
                Playlist
              </a>
               -->
            </div>

          </div>
        </div> <!-- / .row -->
      </div> <!-- / .container -->
    </section>

    <!-- SHAPE -->
    <div class="position-relative">
      <div class="shape shape-bottom shape-fluid-x svg-shim text-light">
        <svg viewBox="0 0 2880 48" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M0 48h2880V0h-720C1442.5 52 720 0 720 0H0v48z" fill="currentColor"/></svg>
      </div>
    </div>

    
    <!-- VIDEO -->
    <section class="pt-2 sticky">
      <div class="container">
        <div class="row justify-content-center">

          <div id="video-container" class="col-9 col-lg-12 mb-5">

          <!-- Video -->

            <!-- 1. The <iframe> (and video player) will replace this <div> tag. -->
            <div id="player" class="sticky"></div>

            <script>
              
              var transcript = [{"text": "Hello everyone.", "timestamp": "00:00:00,140", "timestamp_s": 0.0}, {"text": "Greetings of the day.", "timestamp": "00:00:01,260", "timestamp_s": 1.0}, {"text": "My name is Karthik Akinnapelli and I\u0027m hoping you\u0027re all doing well.", "timestamp": "00:00:02,950", "timestamp_s": 2.0}, {"text": "Today, I\u0027m excited to share the results of a trial conducted to", "timestamp": "00:00:07,750", "timestamp_s": 7.0}, {"text": "evaluate a new oral antibiotic in comparison to Emprixiprofloxacin.", "timestamp": "00:00:12,489", "timestamp_s": 12.0}, {"text": "So why late?", "timestamp": "00:00:18,610", "timestamp_s": 18.0}, {"text": "Let\u0027s dive into the study and look at its key findings.", "timestamp": "00:00:19,599", "timestamp_s": 19.0}, {"text": "So before we jump into the trial information, let me give you a", "timestamp": "00:00:23,169", "timestamp_s": 23.0}, {"text": "little bit background of this trial.", "timestamp": "00:00:26,069", "timestamp_s": 26.0}, {"text": "So why new antibiotic?", "timestamp": "00:00:28,470", "timestamp_s": 28.0}, {"text": "There is a growing concern about increasing fluoroquinolone resistance in", "timestamp": "00:00:30,400", "timestamp_s": 30.0}, {"text": "real world settings, which significantly limits treatment options for uncomplicated", "timestamp": "00:00:35,710", "timestamp_s": 35.0}, {"text": "urinary tract infections in outpatient setting, which leads to hospitalization.", "timestamp": "00:00:41,540", "timestamp_s": 41.0}, {"text": "Now why sulopenum?", "timestamp": "00:00:47,830", "timestamp_s": 47.0}, {"text": "Sulopenum is the first oral theopenum antibiotic specifically", "timestamp": "00:00:49,570", "timestamp_s": 49.0}, {"text": "developed to combat multi drug resistant gram negative uropathogens.", "timestamp": "00:00:53,540", "timestamp_s": 53.0}, {"text": "Neuropathogens are nothing but pathogens responsible for urinary tract infections.", "timestamp": "00:00:59,330", "timestamp_s": 59.0}, {"text": "Now about this study.", "timestamp": "00:01:04,200", "timestamp_s": 64.0}, {"text": "This is a phase 3 double blind study evaluating the efficacy and safety of", "timestamp": "00:01:06,060", "timestamp_s": 66.0}, {"text": "a five day course of sulopenum compared to the standard three day regimen of", "timestamp": "00:01:12,450", "timestamp_s": 72.0}, {"text": "ciprofloxacin in adult women with UUTIs.", "timestamp": "00:01:16,819", "timestamp_s": 76.0}, {"text": "Coming to the end point, the primary end point is a robust composite measure.", "timestamp": "00:01:20,750", "timestamp_s": 80.0}, {"text": "assessing both clinical symptom resolution and microbiological", "timestamp": "00:01:26,220", "timestamp_s": 86.0}, {"text": "eradication at the test of cure visit which is day 12 in the study.", "timestamp": "00:01:30,290", "timestamp_s": 90.0}, {"text": "Now let\u0027s look at enrollment overview.", "timestamp": "00:01:36,620", "timestamp_s": 96.0}, {"text": "A total of 1672 women were enrolled in the trial of which 1660 participants", "timestamp": "00:01:39,720", "timestamp_s": 99.0}, {"text": "were qualified for the safety population, meaning they received", "timestamp": "00:01:48,190", "timestamp_s": 108.0}, {"text": "at least one dose of study drug.", "timestamp": "00:01:52,640", "timestamp_s": 112.0}, {"text": "Whereas 1072 participants qualified into microbiological", "timestamp": "00:01:55,439", "timestamp_s": 115.0}, {"text": "intent to treat population.", "timestamp": "00:02:01,159", "timestamp_s": 121.0}, {"text": "This is where the primary endpoint is evaluated.", "timestamp": "00:02:03,549", "timestamp_s": 123.0}, {"text": "The criteria to qualify into this population is that the", "timestamp": "00:02:06,619", "timestamp_s": 126.0}, {"text": "baseline pathogen should have at least 10 to the 5 CFU per ml.", "timestamp": "00:02:09,889", "timestamp_s": 129.0}, {"text": "CFU is nothing but colony forming units.", "timestamp": "00:02:15,510", "timestamp_s": 135.0}, {"text": "Now, key findings.", "timestamp": "00:02:18,340", "timestamp_s": 138.0}, {"text": "Essertia coli was the predominant pathogen accounting for approximately 85", "timestamp": "00:02:20,700", "timestamp_s": 140.0}, {"text": "percent of all infections in this study.", "timestamp": "00:02:26,089", "timestamp_s": 146.0}, {"text": "Of these, 27 percent demonstrated non susceptibility to ciprofloxacin.", "timestamp": "00:02:29,839", "timestamp_s": 149.0}, {"text": "That is pretty high rate.", "timestamp": "00:02:35,749", "timestamp_s": 155.0}, {"text": "Now second most common pathogen identified was Klebsiella pneumonia.", "timestamp": "00:02:37,700", "timestamp_s": 157.0}, {"text": "Now, looking at resistance insights, around 13.", "timestamp": "00:02:42,589", "timestamp_s": 162.0}, {"text": "5 percent of the total isolates were extended spectrum beta lactamase", "timestamp": "00:02:46,450", "timestamp_s": 166.0}, {"text": "producing, ESBL producing organisms, indicating multi drug resistance.", "timestamp": "00:02:52,250", "timestamp_s": 172.0}, {"text": "Now, let\u0027s look at efficacy results.", "timestamp": "00:02:58,839", "timestamp_s": 178.0}, {"text": "in non susceptible pathogens.", "timestamp": "00:03:01,939", "timestamp_s": 181.0}, {"text": "Sulopenum demonstrated clear superiority over ciprofloxacin in treating non", "timestamp": "00:03:04,869", "timestamp_s": 184.0}, {"text": "susceptible pathogens with a significant treatment difference in efficacy of 26.", "timestamp": "00:03:11,009", "timestamp_s": 191.0}, {"text": "6 percent and a highly significant p value.", "timestamp": "00:03:17,420", "timestamp_s": 197.0}, {"text": "Now, in susceptible pathogens, sulopenum did not achieve non inferiority.", "timestamp": "00:03:21,149", "timestamp_s": 201.0}, {"text": "The response rate for sulopenum was 66.", "timestamp": "00:03:26,519", "timestamp_s": 206.0}, {"text": "8 percent in solo.", "timestamp": "00:03:29,259", "timestamp_s": 209.0}, {"text": "compared to 78.", "timestamp": "00:03:31,159", "timestamp_s": 211.0}, {"text": "6 percent in Cipro.", "timestamp": "00:03:32,179", "timestamp_s": 212.0}, {"text": "Now in overall study population combining both non susceptible and susceptible", "timestamp": "00:03:34,539", "timestamp_s": 214.0}, {"text": "populations, solopenem achieved non inferiority with the response rate of 65.", "timestamp": "00:03:39,279", "timestamp_s": 219.0}, {"text": "6 in solo compared to 67.", "timestamp": "00:03:44,879", "timestamp_s": 224.0}, {"text": "9 in ciprofloxacin.", "timestamp": "00:03:47,940", "timestamp_s": 227.0}, {"text": "So let\u0027s look at clinical response.", "timestamp": "00:03:50,329", "timestamp_s": 230.0}, {"text": "The study evaluated clinical response at various time points", "timestamp": "00:03:53,829", "timestamp_s": 233.0}, {"text": "with the following key findings.", "timestamp": "00:03:57,679", "timestamp_s": 237.0}, {"text": "At initial evaluation at day 5 of the study, solopenem and", "timestamp": "00:04:00,049", "timestamp_s": 240.0}, {"text": "ceprofloxacin demonstrated comparable response rates, 68.", "timestamp": "00:04:04,749", "timestamp_s": 244.0}, {"text": "7 percent solo versus 67.", "timestamp": "00:04:08,519", "timestamp_s": 248.0}, {"text": "3 percent in cipro.", "timestamp": "00:04:11,809", "timestamp_s": 251.0}, {"text": "At day 12, which is at, Primary endpoint, solopenem showed similar", "timestamp": "00:04:13,459", "timestamp_s": 253.0}, {"text": "overall effectiveness in clinical response compared to ciprofloxacin 81.", "timestamp": "00:04:19,359", "timestamp_s": 259.0}, {"text": "1 percent in Sulo versus 84.", "timestamp": "00:04:25,680", "timestamp_s": 265.0}, {"text": "1 percent in Cipro Whereas in the resistant population, solopenem", "timestamp": "00:04:27,679", "timestamp_s": 267.0}, {"text": "clearly exhibited superior efficacy 83 percent in Sulo versus 62.", "timestamp": "00:04:32,809", "timestamp_s": 272.0}, {"text": "6 percent in Cipro Now they also evaluated a follow-up period, which is day 28.", "timestamp": "00:04:38,200", "timestamp_s": 278.0}, {"text": "Both treatment groups maintained a sustained clinical response confirming", "timestamp": "00:04:44,599", "timestamp_s": 284.0}, {"text": "the durability of the treatments.", "timestamp": "00:04:49,729", "timestamp_s": 289.0}, {"text": "Now with good clinical response, why did Opinum did not achieve non-inferiority", "timestamp": "00:04:52,499", "timestamp_s": 292.0}, {"text": "in non susceptible pathogens?", "timestamp": "00:04:59,289", "timestamp_s": 299.0}, {"text": "This is because of a SP impact.", "timestamp": "00:05:01,869", "timestamp_s": 301.0}, {"text": "Like I said, while clinical response rates are very comparable between", "timestamp": "00:05:04,860", "timestamp_s": 304.0}, {"text": "two treatment groups, the difference lay in microbiological outcomes,", "timestamp": "00:05:09,100", "timestamp_s": 309.0}, {"text": "specifically the occurrence of ASB, asymptomatic bacteria, which is", "timestamp": "00:05:13,500", "timestamp_s": 313.0}, {"text": "nothing but patients are clinically clear, but has a positive culture.", "timestamp": "00:05:18,940", "timestamp_s": 318.0}, {"text": "Now, at day 12, ASB was more prevalent in sulopinem group compared to ciprofloxacin.", "timestamp": "00:05:24,450", "timestamp_s": 324.0}, {"text": "15.", "timestamp": "00:05:30,951", "timestamp_s": 330.0}, {"text": "2 percent in Sulo versus 7.", "timestamp": "00:05:31,570", "timestamp_s": 331.0}, {"text": "8 percent in Cipro.", "timestamp": "00:05:34,481", "timestamp_s": 334.0}, {"text": "Despite the higher ASB rates, patients in both groups demonstrated", "timestamp": "00:05:36,430", "timestamp_s": 336.0}, {"text": "equivalent clinical outcomes during follow up period at day 28,", "timestamp": "00:05:41,070", "timestamp_s": 341.0}, {"text": "as we saw in the previous slide.", "timestamp": "00:05:45,280", "timestamp_s": 345.0}, {"text": "This is confirming the durability of the treatment.", "timestamp": "00:05:47,210", "timestamp_s": 347.0}, {"text": "So what\u0027s the conclusion?", "timestamp": "00:05:50,970", "timestamp_s": 350.0}, {"text": "The higher ASB rates with Sulopenum likely reflect the restoration of", "timestamp": "00:05:52,600", "timestamp_s": 352.0}, {"text": "normal urogenital bacterial flora.", "timestamp": "00:05:57,420", "timestamp_s": 357.0}, {"text": "rather than persistent infection highlighting a potential", "timestamp": "00:06:00,115", "timestamp_s": 360.0}, {"text": "microbiological advantage.", "timestamp": "00:06:04,065", "timestamp_s": 364.0}, {"text": "Now, let\u0027s look at resistance emergence.", "timestamp": "00:06:06,145", "timestamp_s": 366.0}, {"text": "So, some of the key observations include resistance development.", "timestamp": "00:06:10,245", "timestamp_s": 370.0}, {"text": "Following treatment with ciprofloxacin, 41.", "timestamp": "00:06:14,535", "timestamp_s": 374.0}, {"text": "7 percent of initially susceptible pathogens developed resistance.", "timestamp": "00:06:17,445", "timestamp_s": 377.0}, {"text": "very high percent indicating significant selective pressure.", "timestamp": "00:06:22,965", "timestamp_s": 382.0}, {"text": "Now genetic changes in pathogens post treatment some pathogens acquired extended", "timestamp": "00:06:27,345", "timestamp_s": 387.0}, {"text": "spectrum beta lactamase ESBL genes compromising multiple antibiotic classes", "timestamp": "00:06:33,755", "timestamp_s": 393.0}, {"text": "and further limiting treatment options.", "timestamp": "00:06:40,925", "timestamp_s": 400.0}, {"text": "Now, looking at sulopenum MIC stability, in contrast, MIC distribution for", "timestamp": "00:06:44,045", "timestamp_s": 404.0}, {"text": "sulopenum remains stable, demonstrating a low risk of resistance development.", "timestamp": "00:06:50,635", "timestamp_s": 410.0}, {"text": "So what\u0027s the conclusion?", "timestamp": "00:06:57,095", "timestamp_s": 417.0}, {"text": "The contrasting effects on bacterial resistance patterns underscored the", "timestamp": "00:06:58,635", "timestamp_s": 418.0}, {"text": "critical importance of antibiotic stewardship and informed drug", "timestamp": "00:07:03,205", "timestamp_s": 423.0}, {"text": "selection in managing UTIs.", "timestamp": "00:07:08,445", "timestamp_s": 428.0}, {"text": "These findings highlight silopenum\u0027s potential as a valuable option in", "timestamp": "00:07:11,155", "timestamp_s": 431.0}, {"text": "combating antibiotic resistance.", "timestamp": "00:07:17,105", "timestamp_s": 437.0}, {"text": "Now, let\u0027s look at safety profile.", "timestamp": "00:07:19,605", "timestamp_s": 439.0}, {"text": "So, both treatment groups showed almost similar safety results.", "timestamp": "00:07:22,425", "timestamp_s": 442.0}, {"text": "Silopenum showed 25 percent of adverse event rate compared", "timestamp": "00:07:26,935", "timestamp_s": 446.0}, {"text": "to ciprofloxacin at 14%.", "timestamp": "00:07:30,265", "timestamp_s": 450.0}, {"text": "And the most common adverse event include headache.", "timestamp": "00:07:33,145", "timestamp_s": 453.0}, {"text": "which is 4.", "timestamp": "00:07:36,320", "timestamp_s": 456.0}, {"text": "2 percent in Sulo versus 3.", "timestamp": "00:07:36,661", "timestamp_s": 456.0}, {"text": "1 percent in Cipro.", "timestamp": "00:07:39,430", "timestamp_s": 459.0}, {"text": "And the next most common adverse event found is nausea.", "timestamp": "00:07:41,960", "timestamp_s": 461.0}, {"text": "3.", "timestamp": "00:07:46,200", "timestamp_s": 466.0}, {"text": "8 percent in Sulo versus 2.", "timestamp": "00:07:46,770", "timestamp_s": 466.0}, {"text": "2 percent in Cipro.", "timestamp": "00:07:48,320", "timestamp_s": 468.0}, {"text": "Diarrhoea, which is GI related, was significantly more", "timestamp": "00:07:50,380", "timestamp_s": 470.0}, {"text": "common with Sulopenum at 12.", "timestamp": "00:07:54,800", "timestamp_s": 474.0}, {"text": "4 percent versus 2.", "timestamp": "00:07:57,700", "timestamp_s": 477.0}, {"text": "5 with a mean duration of three days, but 95 percent of cases resolved", "timestamp": "00:07:59,670", "timestamp_s": 479.0}, {"text": "spontaneously while 5 percent required anti diarrheal medication.", "timestamp": "00:08:06,015", "timestamp_s": 486.0}, {"text": "Other GI effects include nausea and abdominal pain, pretty much very", "timestamp": "00:08:11,345", "timestamp_s": 491.0}, {"text": "common with all antibiotic classes.", "timestamp": "00:08:15,855", "timestamp_s": 495.0}, {"text": "Serious adverse event rates are also similar, 0.", "timestamp": "00:08:18,446", "timestamp_s": 498.0}, {"text": "7 percent in versus 0.", "timestamp": "00:08:22,260", "timestamp_s": 502.0}, {"text": "2 percent in Cipro and of the six serious adverse events on solopenem,", "timestamp": "00:08:23,896", "timestamp_s": 503.0}, {"text": "only two were considered drug related.", "timestamp": "00:08:30,311", "timestamp_s": 510.0}, {"text": "And in the course of the study, no deaths occurred and all the SOEs are", "timestamp": "00:08:33,061", "timestamp_s": 513.0}, {"text": "resolved by the end of the study.", "timestamp": "00:08:38,241", "timestamp_s": 518.0}, {"text": "Now, implications of empirical treatment.", "timestamp": "00:08:40,851", "timestamp_s": 520.0}, {"text": "Similar overall efficacy.", "timestamp": "00:08:44,011", "timestamp_s": 524.0}, {"text": "So, solopenum showed non inferiority to ciprofloxacin in general population", "timestamp": "00:08:45,261", "timestamp_s": 525.0}, {"text": "as we seen in the previous slides.", "timestamp": "00:08:50,711", "timestamp_s": 530.0}, {"text": "Resistant advantage.", "timestamp": "00:08:53,371", "timestamp_s": 533.0}, {"text": "Solopenum showed superiority to ciprofloxacin in non", "timestamp": "00:08:54,961", "timestamp_s": 534.0}, {"text": "susceptible population.", "timestamp": "00:08:58,631", "timestamp_s": 538.0}, {"text": "Reduce risk resistance.", "timestamp": "00:09:00,441", "timestamp_s": 540.0}, {"text": "As discussed in the previous slide, solopenum demonstrated low", "timestamp": "00:09:02,551", "timestamp_s": 542.0}, {"text": "risk of resistance development and giving a treatment option", "timestamp": "00:09:06,241", "timestamp_s": 546.0}, {"text": "for multidrug resistant UTIs.", "timestamp": "00:09:10,011", "timestamp_s": 550.0}, {"text": "Cellopenem showed effectiveness against pathogens that are", "timestamp": "00:09:12,631", "timestamp_s": 552.0}, {"text": "resistant to multiple antibiotics.", "timestamp": "00:09:15,951", "timestamp_s": 555.0}, {"text": "Now, let\u0027s look at some study limitations and considerations.", "timestamp": "00:09:18,831", "timestamp_s": 558.0}, {"text": "Limitations include, the study was conducted before the implementation", "timestamp": "00:09:23,490", "timestamp_s": 563.0}, {"text": "of updated treatment guidelines, which may affect its relevance", "timestamp": "00:09:28,060", "timestamp_s": 568.0}, {"text": "to current clinical practices.", "timestamp": "00:09:33,130", "timestamp_s": 573.0}, {"text": "The inclusion of ASB in the primary endpoint may not fully align with", "timestamp": "00:09:35,610", "timestamp_s": 575.0}, {"text": "real world clinical practice patterns.", "timestamp": "00:09:40,360", "timestamp_s": 580.0}, {"text": "Now, short term follow up limits the ability to assess the long", "timestamp": "00:09:42,820", "timestamp_s": 582.0}, {"text": "term emergence of resistance.", "timestamp": "00:09:46,790", "timestamp_s": 586.0}, {"text": "Coming to the key considerations, results indicate that empiric use of ciprofloxacin", "timestamp": "00:09:48,810", "timestamp_s": 588.0}, {"text": "should be avoided in settings where resistance rates exceed 10%.", "timestamp": "00:09:54,290", "timestamp_s": 594.0}, {"text": "Now, balancing the therapeutic efficacy with the potential", "timestamp": "00:09:59,250", "timestamp_s": 599.0}, {"text": "for mild gastrointestinal side effects is essential.", "timestamp": "00:10:02,350", "timestamp_s": 602.0}, {"text": "So lopinum offers a viable treatment option for multiple drug resistant", "timestamp": "00:10:06,320", "timestamp_s": 606.0}, {"text": "urinary tract infections addressing a critical gap in current treatment options.", "timestamp": "00:10:11,100", "timestamp_s": 611.0}, {"text": "Now, finally conclusions and further future directions Solopenum has", "timestamp": "00:10:17,610", "timestamp_s": 617.0}, {"text": "demonstrated significant efficacy in treating multi drug resistant", "timestamp": "00:10:24,215", "timestamp_s": 624.0}, {"text": "urinary tract infections, providing a crucial alternative to existing", "timestamp": "00:10:29,575", "timestamp_s": 629.0}, {"text": "empirical treatment options.", "timestamp": "00:10:35,035", "timestamp_s": 635.0}, {"text": "Incorporating regional antibiotic resistance data into clinical", "timestamp": "00:10:37,155", "timestamp_s": 637.0}, {"text": "decision making is essential to optimize therapeutic outcomes.", "timestamp": "00:10:40,975", "timestamp_s": 640.0}, {"text": "The study highlights sulopenem\u0027s potential to minimize bacterial", "timestamp": "00:10:45,655", "timestamp_s": 645.0}, {"text": "resistance development while maintaining its therapeutic efficacy.", "timestamp": "00:10:50,105", "timestamp_s": 650.0}, {"text": "There is a critical need to further investigate long term resistance", "timestamp": "00:10:54,765", "timestamp_s": 654.0}, {"text": "patterns and patient outcomes through comprehensive longitudinal studies.", "timestamp": "00:10:59,315", "timestamp_s": 659.0}, {"text": "Finally, continued exploration of sulopinem\u0027s implementation in", "timestamp": "00:11:04,690", "timestamp_s": 664.0}, {"text": "diverse clinical settings will help refine its role in managing", "timestamp": "00:11:09,380", "timestamp_s": 669.0}, {"text": "multi drug resistant infections.", "timestamp": "00:11:13,870", "timestamp_s": 673.0}, {"text": "Thank you so much for giving me this opportunity and take care, bye.", "timestamp": "00:11:16,510", "timestamp_s": 676.0}];
              

              var tag = document.createElement('script');

              tag.src = "https://www.youtube.com/iframe_api";
              var firstScriptTag = document.getElementsByTagName('script')[0];
              firstScriptTag.parentNode.insertBefore(tag, firstScriptTag);

              // 3. This function creates an <iframe> (and YouTube player)
              //    after the API code downloads.
              var player;
              function onYouTubeIframeAPIReady() {
                player = new YT.Player('player', {
                  height: '100%',
                  width: '100%',
                  videoId: '2wCHiRSV_rU',
                  playerVars: {
                    'playsinline': 1
                  },
                  events: {
                    'onReady': onPlayerReady,
                    // 'onStateChange': onPlayerStateChange
                  }
                });
              }
              function onPlayerReady(event) {
                console.log("Player ready");
                var sec = Number(location.href.split("#")[1]);
                if (sec){
                  player.seekTo(sec, true);
                }
                player.playVideo();
                highlightParagraph();
              }
              // find the number of the paragraph
              function findParagraph(sec){
                for (var i = 1; i < transcript.length; i++) {
                  if (transcript[i].timestamp_s > sec){
                    return i - 1;
                  }
                }
                return transcript.length - 1;
              }
              // move the video to the desired second
              function seek(sec){
                if(player){
                  player.playVideo();
                  player.seekTo(sec, true);
                }
                location.href = location.href.split("#")[0] + "#" + sec;
                highlightParagraph(sec);
              }
              // highlight the right paragraph
              var prevParagraph;
              function highlightParagraph(sec) {
                var currentTime = sec;
                if (!currentTime && player) {
                  currentTime = player.getCurrentTime();
                }
                if (!currentTime){
                  console.log("No current time")
                  return;
                }
                var currentParagraph = findParagraph(currentTime);
                if (currentParagraph !== prevParagraph){
                  prevParagraph = currentParagraph;
                  Array.from(document.getElementsByClassName("transcript-chunks")).forEach((e) => {
                    e.classList.remove('text-selected');
                  });
                  var body = document.getElementById("chunk-"+currentParagraph);
                  body.classList.add('text-selected');
                }
              }
              time_update_interval = setInterval(highlightParagraph, 1000);
            </script>
          </div>
        </div> <!-- / .row -->
      </div> <!-- / .container -->
    </section>
    

    <!-- CONTENT -->
    <section class="pt-2">
      <div class="container">
        <div class="row justify-content-center">

          <div class="col-12 mb-5">
            <h1>
              Combatting Antibiotic Resistance in UTI Treatment: Phase 3 Insights on Sulopenem vs. Ciprofloxacin
            </h1>
            
            <h3 class="bg-white">
              Video size:
              <a href="javascript:void(0);" onclick="resizeVideo(25)"><i class="fe fe-zoom-out me-2"></i></a>
              <a href="javascript:void(0);" onclick="resizeVideo(50)"><i class="fe fe-zoom-in me-2"></i></a>
            </h3>
            
          </div>

          <div class="col-12 mb-5">
            <h3>
              Abstract
            </h3>
<!-- Text -->
<p>Discover how we’re revolutionizing UTI treatment in the fight against antibiotic resistance! Learn about sulopenem&rsquo;s groundbreaking success against multi-drug resistant pathogens, offering hope where other antibiotics fail. Join us for game-changing insights into the future of infection management!</p>
<!-- End Text -->
          </div>

          
          

          <div class="col-12 mb-5">
            <h3>
              Summary
            </h3>
            <ul>
              
            </ul>
          </div>

          <div class="col-12 mb-5">
            <h3>
              Transcript
            </h3>
            <span class="text-muted">
              This transcript was autogenerated. To make changes, <a href="https://github.com/conf42/src/edit/main/./srt/devops2025_Karthik_Akinapelli.srt" target="_blank">submit a PR</a>.
            </span>
            <div>
            
            <span id="chunk-0" class="transcript-chunks" onclick="console.log('00:00:00,140'); seek(0.0)">
              Hello everyone.
            </span>
            
            <span id="chunk-1" class="transcript-chunks" onclick="console.log('00:00:01,260'); seek(1.0)">
              Greetings of the day.
            </span>
            
            <span id="chunk-2" class="transcript-chunks" onclick="console.log('00:00:02,950'); seek(2.0)">
              My name is Karthik Akinnapelli and I'm hoping you're all doing well.
            </span>
            
            <span id="chunk-3" class="transcript-chunks" onclick="console.log('00:00:07,750'); seek(7.0)">
              Today, I'm excited to share the results of a trial conducted to
            </span>
            
            <span id="chunk-4" class="transcript-chunks" onclick="console.log('00:00:12,489'); seek(12.0)">
              evaluate a new oral antibiotic in comparison to Emprixiprofloxacin.
            </span>
            
            <span id="chunk-5" class="transcript-chunks" onclick="console.log('00:00:18,610'); seek(18.0)">
              So why late?
            </span>
            
            <span id="chunk-6" class="transcript-chunks" onclick="console.log('00:00:19,599'); seek(19.0)">
              Let's dive into the study and look at its key findings.
            </span>
            
            <span id="chunk-7" class="transcript-chunks" onclick="console.log('00:00:23,169'); seek(23.0)">
              So before we jump into the trial information, let me give you a
            </span>
            
            <span id="chunk-8" class="transcript-chunks" onclick="console.log('00:00:26,069'); seek(26.0)">
              little bit background of this trial.
            </span>
            
            <span id="chunk-9" class="transcript-chunks" onclick="console.log('00:00:28,470'); seek(28.0)">
              So why new antibiotic?
            </span>
            
            <span id="chunk-10" class="transcript-chunks" onclick="console.log('00:00:30,400'); seek(30.0)">
              There is a growing concern about increasing fluoroquinolone resistance in
            </span>
            
            <span id="chunk-11" class="transcript-chunks" onclick="console.log('00:00:35,710'); seek(35.0)">
              real world settings, which significantly limits treatment options for uncomplicated
            </span>
            
            <span id="chunk-12" class="transcript-chunks" onclick="console.log('00:00:41,540'); seek(41.0)">
              urinary tract infections in outpatient setting, which leads to hospitalization.
            </span>
            
            <span id="chunk-13" class="transcript-chunks" onclick="console.log('00:00:47,830'); seek(47.0)">
              Now why sulopenum?
            </span>
            
            <span id="chunk-14" class="transcript-chunks" onclick="console.log('00:00:49,570'); seek(49.0)">
              Sulopenum is the first oral theopenum antibiotic specifically
            </span>
            
            <span id="chunk-15" class="transcript-chunks" onclick="console.log('00:00:53,540'); seek(53.0)">
              developed to combat multi drug resistant gram negative uropathogens.
            </span>
            
            <span id="chunk-16" class="transcript-chunks" onclick="console.log('00:00:59,330'); seek(59.0)">
              Neuropathogens are nothing but pathogens responsible for urinary tract infections.
            </span>
            
            <span id="chunk-17" class="transcript-chunks" onclick="console.log('00:01:04,200'); seek(64.0)">
              Now about this study.
            </span>
            
            <span id="chunk-18" class="transcript-chunks" onclick="console.log('00:01:06,060'); seek(66.0)">
              This is a phase 3 double blind study evaluating the efficacy and safety of
            </span>
            
            <span id="chunk-19" class="transcript-chunks" onclick="console.log('00:01:12,450'); seek(72.0)">
              a five day course of sulopenum compared to the standard three day regimen of
            </span>
            
            <span id="chunk-20" class="transcript-chunks" onclick="console.log('00:01:16,819'); seek(76.0)">
              ciprofloxacin in adult women with UUTIs.
            </span>
            
            <span id="chunk-21" class="transcript-chunks" onclick="console.log('00:01:20,750'); seek(80.0)">
              Coming to the end point, the primary end point is a robust composite measure.
            </span>
            
            <span id="chunk-22" class="transcript-chunks" onclick="console.log('00:01:26,220'); seek(86.0)">
              assessing both clinical symptom resolution and microbiological
            </span>
            
            <span id="chunk-23" class="transcript-chunks" onclick="console.log('00:01:30,290'); seek(90.0)">
              eradication at the test of cure visit which is day 12 in the study.
            </span>
            
            <span id="chunk-24" class="transcript-chunks" onclick="console.log('00:01:36,620'); seek(96.0)">
              Now let's look at enrollment overview.
            </span>
            
            <span id="chunk-25" class="transcript-chunks" onclick="console.log('00:01:39,720'); seek(99.0)">
              A total of 1672 women were enrolled in the trial of which 1660 participants
            </span>
            
            <span id="chunk-26" class="transcript-chunks" onclick="console.log('00:01:48,190'); seek(108.0)">
              were qualified for the safety population, meaning they received
            </span>
            
            <span id="chunk-27" class="transcript-chunks" onclick="console.log('00:01:52,640'); seek(112.0)">
              at least one dose of study drug.
            </span>
            
            <span id="chunk-28" class="transcript-chunks" onclick="console.log('00:01:55,439'); seek(115.0)">
              Whereas 1072 participants qualified into microbiological
            </span>
            
            <span id="chunk-29" class="transcript-chunks" onclick="console.log('00:02:01,159'); seek(121.0)">
              intent to treat population.
            </span>
            
            <span id="chunk-30" class="transcript-chunks" onclick="console.log('00:02:03,549'); seek(123.0)">
              This is where the primary endpoint is evaluated.
            </span>
            
            <span id="chunk-31" class="transcript-chunks" onclick="console.log('00:02:06,619'); seek(126.0)">
              The criteria to qualify into this population is that the
            </span>
            
            <span id="chunk-32" class="transcript-chunks" onclick="console.log('00:02:09,889'); seek(129.0)">
              baseline pathogen should have at least 10 to the 5 CFU per ml.
            </span>
            
            <span id="chunk-33" class="transcript-chunks" onclick="console.log('00:02:15,510'); seek(135.0)">
              CFU is nothing but colony forming units.
            </span>
            
            <span id="chunk-34" class="transcript-chunks" onclick="console.log('00:02:18,340'); seek(138.0)">
              Now, key findings.
            </span>
            
            <span id="chunk-35" class="transcript-chunks" onclick="console.log('00:02:20,700'); seek(140.0)">
              Essertia coli was the predominant pathogen accounting for approximately 85
            </span>
            
            <span id="chunk-36" class="transcript-chunks" onclick="console.log('00:02:26,089'); seek(146.0)">
              percent of all infections in this study.
            </span>
            
            <span id="chunk-37" class="transcript-chunks" onclick="console.log('00:02:29,839'); seek(149.0)">
              Of these, 27 percent demonstrated non susceptibility to ciprofloxacin.
            </span>
            
            <span id="chunk-38" class="transcript-chunks" onclick="console.log('00:02:35,749'); seek(155.0)">
              That is pretty high rate.
            </span>
            
            <span id="chunk-39" class="transcript-chunks" onclick="console.log('00:02:37,700'); seek(157.0)">
              Now second most common pathogen identified was Klebsiella pneumonia.
            </span>
            
            <span id="chunk-40" class="transcript-chunks" onclick="console.log('00:02:42,589'); seek(162.0)">
              Now, looking at resistance insights, around 13.
            </span>
            
            <span id="chunk-41" class="transcript-chunks" onclick="console.log('00:02:46,450'); seek(166.0)">
              5 percent of the total isolates were extended spectrum beta lactamase
            </span>
            
            <span id="chunk-42" class="transcript-chunks" onclick="console.log('00:02:52,250'); seek(172.0)">
              producing, ESBL producing organisms, indicating multi drug resistance.
            </span>
            
            <span id="chunk-43" class="transcript-chunks" onclick="console.log('00:02:58,839'); seek(178.0)">
              Now, let's look at efficacy results.
            </span>
            
            <span id="chunk-44" class="transcript-chunks" onclick="console.log('00:03:01,939'); seek(181.0)">
              in non susceptible pathogens.
            </span>
            
            <span id="chunk-45" class="transcript-chunks" onclick="console.log('00:03:04,869'); seek(184.0)">
              Sulopenum demonstrated clear superiority over ciprofloxacin in treating non
            </span>
            
            <span id="chunk-46" class="transcript-chunks" onclick="console.log('00:03:11,009'); seek(191.0)">
              susceptible pathogens with a significant treatment difference in efficacy of 26.
            </span>
            
            <span id="chunk-47" class="transcript-chunks" onclick="console.log('00:03:17,420'); seek(197.0)">
              6 percent and a highly significant p value.
            </span>
            
            <span id="chunk-48" class="transcript-chunks" onclick="console.log('00:03:21,149'); seek(201.0)">
              Now, in susceptible pathogens, sulopenum did not achieve non inferiority.
            </span>
            
            <span id="chunk-49" class="transcript-chunks" onclick="console.log('00:03:26,519'); seek(206.0)">
              The response rate for sulopenum was 66.
            </span>
            
            <span id="chunk-50" class="transcript-chunks" onclick="console.log('00:03:29,259'); seek(209.0)">
              8 percent in solo.
            </span>
            
            <span id="chunk-51" class="transcript-chunks" onclick="console.log('00:03:31,159'); seek(211.0)">
              compared to 78.
            </span>
            
            <span id="chunk-52" class="transcript-chunks" onclick="console.log('00:03:32,179'); seek(212.0)">
              6 percent in Cipro.
            </span>
            
            <span id="chunk-53" class="transcript-chunks" onclick="console.log('00:03:34,539'); seek(214.0)">
              Now in overall study population combining both non susceptible and susceptible
            </span>
            
            <span id="chunk-54" class="transcript-chunks" onclick="console.log('00:03:39,279'); seek(219.0)">
              populations, solopenem achieved non inferiority with the response rate of 65.
            </span>
            
            <span id="chunk-55" class="transcript-chunks" onclick="console.log('00:03:44,879'); seek(224.0)">
              6 in solo compared to 67.
            </span>
            
            <span id="chunk-56" class="transcript-chunks" onclick="console.log('00:03:47,940'); seek(227.0)">
              9 in ciprofloxacin.
            </span>
            
            <span id="chunk-57" class="transcript-chunks" onclick="console.log('00:03:50,329'); seek(230.0)">
              So let's look at clinical response.
            </span>
            
            <span id="chunk-58" class="transcript-chunks" onclick="console.log('00:03:53,829'); seek(233.0)">
              The study evaluated clinical response at various time points
            </span>
            
            <span id="chunk-59" class="transcript-chunks" onclick="console.log('00:03:57,679'); seek(237.0)">
              with the following key findings.
            </span>
            
            <span id="chunk-60" class="transcript-chunks" onclick="console.log('00:04:00,049'); seek(240.0)">
              At initial evaluation at day 5 of the study, solopenem and
            </span>
            
            <span id="chunk-61" class="transcript-chunks" onclick="console.log('00:04:04,749'); seek(244.0)">
              ceprofloxacin demonstrated comparable response rates, 68.
            </span>
            
            <span id="chunk-62" class="transcript-chunks" onclick="console.log('00:04:08,519'); seek(248.0)">
              7 percent solo versus 67.
            </span>
            
            <span id="chunk-63" class="transcript-chunks" onclick="console.log('00:04:11,809'); seek(251.0)">
              3 percent in cipro.
            </span>
            
            <span id="chunk-64" class="transcript-chunks" onclick="console.log('00:04:13,459'); seek(253.0)">
              At day 12, which is at, Primary endpoint, solopenem showed similar
            </span>
            
            <span id="chunk-65" class="transcript-chunks" onclick="console.log('00:04:19,359'); seek(259.0)">
              overall effectiveness in clinical response compared to ciprofloxacin 81.
            </span>
            
            <span id="chunk-66" class="transcript-chunks" onclick="console.log('00:04:25,680'); seek(265.0)">
              1 percent in Sulo versus 84.
            </span>
            
            <span id="chunk-67" class="transcript-chunks" onclick="console.log('00:04:27,679'); seek(267.0)">
              1 percent in Cipro Whereas in the resistant population, solopenem
            </span>
            
            <span id="chunk-68" class="transcript-chunks" onclick="console.log('00:04:32,809'); seek(272.0)">
              clearly exhibited superior efficacy 83 percent in Sulo versus 62.
            </span>
            
            <span id="chunk-69" class="transcript-chunks" onclick="console.log('00:04:38,200'); seek(278.0)">
              6 percent in Cipro Now they also evaluated a follow-up period, which is day 28.
            </span>
            
            <span id="chunk-70" class="transcript-chunks" onclick="console.log('00:04:44,599'); seek(284.0)">
              Both treatment groups maintained a sustained clinical response confirming
            </span>
            
            <span id="chunk-71" class="transcript-chunks" onclick="console.log('00:04:49,729'); seek(289.0)">
              the durability of the treatments.
            </span>
            
            <span id="chunk-72" class="transcript-chunks" onclick="console.log('00:04:52,499'); seek(292.0)">
              Now with good clinical response, why did Opinum did not achieve non-inferiority
            </span>
            
            <span id="chunk-73" class="transcript-chunks" onclick="console.log('00:04:59,289'); seek(299.0)">
              in non susceptible pathogens?
            </span>
            
            <span id="chunk-74" class="transcript-chunks" onclick="console.log('00:05:01,869'); seek(301.0)">
              This is because of a SP impact.
            </span>
            
            <span id="chunk-75" class="transcript-chunks" onclick="console.log('00:05:04,860'); seek(304.0)">
              Like I said, while clinical response rates are very comparable between
            </span>
            
            <span id="chunk-76" class="transcript-chunks" onclick="console.log('00:05:09,100'); seek(309.0)">
              two treatment groups, the difference lay in microbiological outcomes,
            </span>
            
            <span id="chunk-77" class="transcript-chunks" onclick="console.log('00:05:13,500'); seek(313.0)">
              specifically the occurrence of ASB, asymptomatic bacteria, which is
            </span>
            
            <span id="chunk-78" class="transcript-chunks" onclick="console.log('00:05:18,940'); seek(318.0)">
              nothing but patients are clinically clear, but has a positive culture.
            </span>
            
            <span id="chunk-79" class="transcript-chunks" onclick="console.log('00:05:24,450'); seek(324.0)">
              Now, at day 12, ASB was more prevalent in sulopinem group compared to ciprofloxacin.
            </span>
            
            <span id="chunk-80" class="transcript-chunks" onclick="console.log('00:05:30,951'); seek(330.0)">
              15.
            </span>
            
            <span id="chunk-81" class="transcript-chunks" onclick="console.log('00:05:31,570'); seek(331.0)">
              2 percent in Sulo versus 7.
            </span>
            
            <span id="chunk-82" class="transcript-chunks" onclick="console.log('00:05:34,481'); seek(334.0)">
              8 percent in Cipro.
            </span>
            
            <span id="chunk-83" class="transcript-chunks" onclick="console.log('00:05:36,430'); seek(336.0)">
              Despite the higher ASB rates, patients in both groups demonstrated
            </span>
            
            <span id="chunk-84" class="transcript-chunks" onclick="console.log('00:05:41,070'); seek(341.0)">
              equivalent clinical outcomes during follow up period at day 28,
            </span>
            
            <span id="chunk-85" class="transcript-chunks" onclick="console.log('00:05:45,280'); seek(345.0)">
              as we saw in the previous slide.
            </span>
            
            <span id="chunk-86" class="transcript-chunks" onclick="console.log('00:05:47,210'); seek(347.0)">
              This is confirming the durability of the treatment.
            </span>
            
            <span id="chunk-87" class="transcript-chunks" onclick="console.log('00:05:50,970'); seek(350.0)">
              So what's the conclusion?
            </span>
            
            <span id="chunk-88" class="transcript-chunks" onclick="console.log('00:05:52,600'); seek(352.0)">
              The higher ASB rates with Sulopenum likely reflect the restoration of
            </span>
            
            <span id="chunk-89" class="transcript-chunks" onclick="console.log('00:05:57,420'); seek(357.0)">
              normal urogenital bacterial flora.
            </span>
            
            <span id="chunk-90" class="transcript-chunks" onclick="console.log('00:06:00,115'); seek(360.0)">
              rather than persistent infection highlighting a potential
            </span>
            
            <span id="chunk-91" class="transcript-chunks" onclick="console.log('00:06:04,065'); seek(364.0)">
              microbiological advantage.
            </span>
            
            <span id="chunk-92" class="transcript-chunks" onclick="console.log('00:06:06,145'); seek(366.0)">
              Now, let's look at resistance emergence.
            </span>
            
            <span id="chunk-93" class="transcript-chunks" onclick="console.log('00:06:10,245'); seek(370.0)">
              So, some of the key observations include resistance development.
            </span>
            
            <span id="chunk-94" class="transcript-chunks" onclick="console.log('00:06:14,535'); seek(374.0)">
              Following treatment with ciprofloxacin, 41.
            </span>
            
            <span id="chunk-95" class="transcript-chunks" onclick="console.log('00:06:17,445'); seek(377.0)">
              7 percent of initially susceptible pathogens developed resistance.
            </span>
            
            <span id="chunk-96" class="transcript-chunks" onclick="console.log('00:06:22,965'); seek(382.0)">
              very high percent indicating significant selective pressure.
            </span>
            
            <span id="chunk-97" class="transcript-chunks" onclick="console.log('00:06:27,345'); seek(387.0)">
              Now genetic changes in pathogens post treatment some pathogens acquired extended
            </span>
            
            <span id="chunk-98" class="transcript-chunks" onclick="console.log('00:06:33,755'); seek(393.0)">
              spectrum beta lactamase ESBL genes compromising multiple antibiotic classes
            </span>
            
            <span id="chunk-99" class="transcript-chunks" onclick="console.log('00:06:40,925'); seek(400.0)">
              and further limiting treatment options.
            </span>
            
            <span id="chunk-100" class="transcript-chunks" onclick="console.log('00:06:44,045'); seek(404.0)">
              Now, looking at sulopenum MIC stability, in contrast, MIC distribution for
            </span>
            
            <span id="chunk-101" class="transcript-chunks" onclick="console.log('00:06:50,635'); seek(410.0)">
              sulopenum remains stable, demonstrating a low risk of resistance development.
            </span>
            
            <span id="chunk-102" class="transcript-chunks" onclick="console.log('00:06:57,095'); seek(417.0)">
              So what's the conclusion?
            </span>
            
            <span id="chunk-103" class="transcript-chunks" onclick="console.log('00:06:58,635'); seek(418.0)">
              The contrasting effects on bacterial resistance patterns underscored the
            </span>
            
            <span id="chunk-104" class="transcript-chunks" onclick="console.log('00:07:03,205'); seek(423.0)">
              critical importance of antibiotic stewardship and informed drug
            </span>
            
            <span id="chunk-105" class="transcript-chunks" onclick="console.log('00:07:08,445'); seek(428.0)">
              selection in managing UTIs.
            </span>
            
            <span id="chunk-106" class="transcript-chunks" onclick="console.log('00:07:11,155'); seek(431.0)">
              These findings highlight silopenum's potential as a valuable option in
            </span>
            
            <span id="chunk-107" class="transcript-chunks" onclick="console.log('00:07:17,105'); seek(437.0)">
              combating antibiotic resistance.
            </span>
            
            <span id="chunk-108" class="transcript-chunks" onclick="console.log('00:07:19,605'); seek(439.0)">
              Now, let's look at safety profile.
            </span>
            
            <span id="chunk-109" class="transcript-chunks" onclick="console.log('00:07:22,425'); seek(442.0)">
              So, both treatment groups showed almost similar safety results.
            </span>
            
            <span id="chunk-110" class="transcript-chunks" onclick="console.log('00:07:26,935'); seek(446.0)">
              Silopenum showed 25 percent of adverse event rate compared
            </span>
            
            <span id="chunk-111" class="transcript-chunks" onclick="console.log('00:07:30,265'); seek(450.0)">
              to ciprofloxacin at 14%.
            </span>
            
            <span id="chunk-112" class="transcript-chunks" onclick="console.log('00:07:33,145'); seek(453.0)">
              And the most common adverse event include headache.
            </span>
            
            <span id="chunk-113" class="transcript-chunks" onclick="console.log('00:07:36,320'); seek(456.0)">
              which is 4.
            </span>
            
            <span id="chunk-114" class="transcript-chunks" onclick="console.log('00:07:36,661'); seek(456.0)">
              2 percent in Sulo versus 3.
            </span>
            
            <span id="chunk-115" class="transcript-chunks" onclick="console.log('00:07:39,430'); seek(459.0)">
              1 percent in Cipro.
            </span>
            
            <span id="chunk-116" class="transcript-chunks" onclick="console.log('00:07:41,960'); seek(461.0)">
              And the next most common adverse event found is nausea.
            </span>
            
            <span id="chunk-117" class="transcript-chunks" onclick="console.log('00:07:46,200'); seek(466.0)">
              3.
            </span>
            
            <span id="chunk-118" class="transcript-chunks" onclick="console.log('00:07:46,770'); seek(466.0)">
              8 percent in Sulo versus 2.
            </span>
            
            <span id="chunk-119" class="transcript-chunks" onclick="console.log('00:07:48,320'); seek(468.0)">
              2 percent in Cipro.
            </span>
            
            <span id="chunk-120" class="transcript-chunks" onclick="console.log('00:07:50,380'); seek(470.0)">
              Diarrhoea, which is GI related, was significantly more
            </span>
            
            <span id="chunk-121" class="transcript-chunks" onclick="console.log('00:07:54,800'); seek(474.0)">
              common with Sulopenum at 12.
            </span>
            
            <span id="chunk-122" class="transcript-chunks" onclick="console.log('00:07:57,700'); seek(477.0)">
              4 percent versus 2.
            </span>
            
            <span id="chunk-123" class="transcript-chunks" onclick="console.log('00:07:59,670'); seek(479.0)">
              5 with a mean duration of three days, but 95 percent of cases resolved
            </span>
            
            <span id="chunk-124" class="transcript-chunks" onclick="console.log('00:08:06,015'); seek(486.0)">
              spontaneously while 5 percent required anti diarrheal medication.
            </span>
            
            <span id="chunk-125" class="transcript-chunks" onclick="console.log('00:08:11,345'); seek(491.0)">
              Other GI effects include nausea and abdominal pain, pretty much very
            </span>
            
            <span id="chunk-126" class="transcript-chunks" onclick="console.log('00:08:15,855'); seek(495.0)">
              common with all antibiotic classes.
            </span>
            
            <span id="chunk-127" class="transcript-chunks" onclick="console.log('00:08:18,446'); seek(498.0)">
              Serious adverse event rates are also similar, 0.
            </span>
            
            <span id="chunk-128" class="transcript-chunks" onclick="console.log('00:08:22,260'); seek(502.0)">
              7 percent in versus 0.
            </span>
            
            <span id="chunk-129" class="transcript-chunks" onclick="console.log('00:08:23,896'); seek(503.0)">
              2 percent in Cipro and of the six serious adverse events on solopenem,
            </span>
            
            <span id="chunk-130" class="transcript-chunks" onclick="console.log('00:08:30,311'); seek(510.0)">
              only two were considered drug related.
            </span>
            
            <span id="chunk-131" class="transcript-chunks" onclick="console.log('00:08:33,061'); seek(513.0)">
              And in the course of the study, no deaths occurred and all the SOEs are
            </span>
            
            <span id="chunk-132" class="transcript-chunks" onclick="console.log('00:08:38,241'); seek(518.0)">
              resolved by the end of the study.
            </span>
            
            <span id="chunk-133" class="transcript-chunks" onclick="console.log('00:08:40,851'); seek(520.0)">
              Now, implications of empirical treatment.
            </span>
            
            <span id="chunk-134" class="transcript-chunks" onclick="console.log('00:08:44,011'); seek(524.0)">
              Similar overall efficacy.
            </span>
            
            <span id="chunk-135" class="transcript-chunks" onclick="console.log('00:08:45,261'); seek(525.0)">
              So, solopenum showed non inferiority to ciprofloxacin in general population
            </span>
            
            <span id="chunk-136" class="transcript-chunks" onclick="console.log('00:08:50,711'); seek(530.0)">
              as we seen in the previous slides.
            </span>
            
            <span id="chunk-137" class="transcript-chunks" onclick="console.log('00:08:53,371'); seek(533.0)">
              Resistant advantage.
            </span>
            
            <span id="chunk-138" class="transcript-chunks" onclick="console.log('00:08:54,961'); seek(534.0)">
              Solopenum showed superiority to ciprofloxacin in non
            </span>
            
            <span id="chunk-139" class="transcript-chunks" onclick="console.log('00:08:58,631'); seek(538.0)">
              susceptible population.
            </span>
            
            <span id="chunk-140" class="transcript-chunks" onclick="console.log('00:09:00,441'); seek(540.0)">
              Reduce risk resistance.
            </span>
            
            <span id="chunk-141" class="transcript-chunks" onclick="console.log('00:09:02,551'); seek(542.0)">
              As discussed in the previous slide, solopenum demonstrated low
            </span>
            
            <span id="chunk-142" class="transcript-chunks" onclick="console.log('00:09:06,241'); seek(546.0)">
              risk of resistance development and giving a treatment option
            </span>
            
            <span id="chunk-143" class="transcript-chunks" onclick="console.log('00:09:10,011'); seek(550.0)">
              for multidrug resistant UTIs.
            </span>
            
            <span id="chunk-144" class="transcript-chunks" onclick="console.log('00:09:12,631'); seek(552.0)">
              Cellopenem showed effectiveness against pathogens that are
            </span>
            
            <span id="chunk-145" class="transcript-chunks" onclick="console.log('00:09:15,951'); seek(555.0)">
              resistant to multiple antibiotics.
            </span>
            
            <span id="chunk-146" class="transcript-chunks" onclick="console.log('00:09:18,831'); seek(558.0)">
              Now, let's look at some study limitations and considerations.
            </span>
            
            <span id="chunk-147" class="transcript-chunks" onclick="console.log('00:09:23,490'); seek(563.0)">
              Limitations include, the study was conducted before the implementation
            </span>
            
            <span id="chunk-148" class="transcript-chunks" onclick="console.log('00:09:28,060'); seek(568.0)">
              of updated treatment guidelines, which may affect its relevance
            </span>
            
            <span id="chunk-149" class="transcript-chunks" onclick="console.log('00:09:33,130'); seek(573.0)">
              to current clinical practices.
            </span>
            
            <span id="chunk-150" class="transcript-chunks" onclick="console.log('00:09:35,610'); seek(575.0)">
              The inclusion of ASB in the primary endpoint may not fully align with
            </span>
            
            <span id="chunk-151" class="transcript-chunks" onclick="console.log('00:09:40,360'); seek(580.0)">
              real world clinical practice patterns.
            </span>
            
            <span id="chunk-152" class="transcript-chunks" onclick="console.log('00:09:42,820'); seek(582.0)">
              Now, short term follow up limits the ability to assess the long
            </span>
            
            <span id="chunk-153" class="transcript-chunks" onclick="console.log('00:09:46,790'); seek(586.0)">
              term emergence of resistance.
            </span>
            
            <span id="chunk-154" class="transcript-chunks" onclick="console.log('00:09:48,810'); seek(588.0)">
              Coming to the key considerations, results indicate that empiric use of ciprofloxacin
            </span>
            
            <span id="chunk-155" class="transcript-chunks" onclick="console.log('00:09:54,290'); seek(594.0)">
              should be avoided in settings where resistance rates exceed 10%.
            </span>
            
            <span id="chunk-156" class="transcript-chunks" onclick="console.log('00:09:59,250'); seek(599.0)">
              Now, balancing the therapeutic efficacy with the potential
            </span>
            
            <span id="chunk-157" class="transcript-chunks" onclick="console.log('00:10:02,350'); seek(602.0)">
              for mild gastrointestinal side effects is essential.
            </span>
            
            <span id="chunk-158" class="transcript-chunks" onclick="console.log('00:10:06,320'); seek(606.0)">
              So lopinum offers a viable treatment option for multiple drug resistant
            </span>
            
            <span id="chunk-159" class="transcript-chunks" onclick="console.log('00:10:11,100'); seek(611.0)">
              urinary tract infections addressing a critical gap in current treatment options.
            </span>
            
            <span id="chunk-160" class="transcript-chunks" onclick="console.log('00:10:17,610'); seek(617.0)">
              Now, finally conclusions and further future directions Solopenum has
            </span>
            
            <span id="chunk-161" class="transcript-chunks" onclick="console.log('00:10:24,215'); seek(624.0)">
              demonstrated significant efficacy in treating multi drug resistant
            </span>
            
            <span id="chunk-162" class="transcript-chunks" onclick="console.log('00:10:29,575'); seek(629.0)">
              urinary tract infections, providing a crucial alternative to existing
            </span>
            
            <span id="chunk-163" class="transcript-chunks" onclick="console.log('00:10:35,035'); seek(635.0)">
              empirical treatment options.
            </span>
            
            <span id="chunk-164" class="transcript-chunks" onclick="console.log('00:10:37,155'); seek(637.0)">
              Incorporating regional antibiotic resistance data into clinical
            </span>
            
            <span id="chunk-165" class="transcript-chunks" onclick="console.log('00:10:40,975'); seek(640.0)">
              decision making is essential to optimize therapeutic outcomes.
            </span>
            
            <span id="chunk-166" class="transcript-chunks" onclick="console.log('00:10:45,655'); seek(645.0)">
              The study highlights sulopenem's potential to minimize bacterial
            </span>
            
            <span id="chunk-167" class="transcript-chunks" onclick="console.log('00:10:50,105'); seek(650.0)">
              resistance development while maintaining its therapeutic efficacy.
            </span>
            
            <span id="chunk-168" class="transcript-chunks" onclick="console.log('00:10:54,765'); seek(654.0)">
              There is a critical need to further investigate long term resistance
            </span>
            
            <span id="chunk-169" class="transcript-chunks" onclick="console.log('00:10:59,315'); seek(659.0)">
              patterns and patient outcomes through comprehensive longitudinal studies.
            </span>
            
            <span id="chunk-170" class="transcript-chunks" onclick="console.log('00:11:04,690'); seek(664.0)">
              Finally, continued exploration of sulopinem's implementation in
            </span>
            
            <span id="chunk-171" class="transcript-chunks" onclick="console.log('00:11:09,380'); seek(669.0)">
              diverse clinical settings will help refine its role in managing
            </span>
            
            <span id="chunk-172" class="transcript-chunks" onclick="console.log('00:11:13,870'); seek(673.0)">
              multi drug resistant infections.
            </span>
            
            <span id="chunk-173" class="transcript-chunks" onclick="console.log('00:11:16,510'); seek(676.0)">
              Thank you so much for giving me this opportunity and take care, bye.
            </span>
            
            </div>
          </div>
          
          

          
          <div class="col-12 mb-5">
            <h3>
              Slides
            </h3>
            <iframe src="https://conf42.github.io/static/slides/Karthik%20Akinapelli%20-%20Conf42%20DevOps%202025.pdf" width="100%" height="500px"></iframe>
            <a href="https://conf42.github.io/static/slides/Karthik%20Akinapelli%20-%20Conf42%20DevOps%202025.pdf" class="btn btn-xs btn-info shadow lift" style="background-color: #5F3202;" target="_blank">
              <i class="fe fe-paperclip me-2"></i>
              Download slides (PDF)
            </a>
          </div>
          

          <div class="col-12 mb-2 text-center">
            <div class="text-center mb-5">
              <a href="https://www.conf42.com/devops2025" class="btn btn-sm btn-danger shadow lift" style="background-color: #5F3202;">
                <i class="fe fe-grid me-2"></i>
                See all 58 talks at this event!
              </a>
            </div>
          </div>
        </div> <!-- / .row -->
      </div> <!-- / .container -->
    </section>

    <!-- PHOTO -->
    <section class="pt-8 pb-6">
      <div class="container">

        <div class="row align-items-center">
          <div class="col-12 col-md-6 col-lg-7">

            <div class="mb-8 mb-md-0">

              <!-- Image -->
              <img src="https://conf42.github.io/static/headshots/Karthik%20Akinapelli_devops.png" alt="..." class="screenshot img-fluid mw-md-110 float-end me-md-6 mb-6 mb-md-0">

            </div>

          </div>
          <div class="col-12 col-md-6 col-lg-5">

            <!-- List -->
            <div class="d-flex">

              <!-- Body -->
              <div class="ms-5">

                <!-- Author 1 -->
                <h2 class="me-2">
                  Karthik Akinapelli
                </h2>
                <h3 class="me-2">
                  <span class="text-muted">
                    Associate Director, Statistical Programing @ Takeda
                  </span>
                </h3>

                <p class="text-uppercase text-muted me-2 mb-3">
                  
                  <a href="https://www.linkedin.com/in/karthik-akinapelli-74200b20/" target="_blank" class="mr-3">
                    <img src="./assets/img/icons/social/linkedin.svg" class="list-social-icon" alt="Karthik Akinapelli's LinkedIn account" />
                  </a>
                  
                  
                </p>
                

                <br />

                <a
                  href="https://twitter.com/share?ref_src=twsrc%5Etfw"
                  class="twitter-share-button"

                  data-text="Check out this talk by Karthik Akinapelli"
                  data-url="https://www.conf42.com/devops2025"
                  data-via="conf42com"
                  data-related=""
                  data-show-count="false"
                >
                  Tweet
                </a>
                <script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>

                <br />

                <script src="https://platform.linkedin.com/in.js" type="text/javascript">lang: en_US</script>
                <script type="IN/Share" data-url="https://www.conf42.com/devops2025"></script>
              </div>

            </div>
          </div>
        </div> <!-- / .row -->
      </div> <!-- / .container -->
    </section>






    <!-- WELCOME -->
    <section class="pt-8 pt-md-11 pb-10 pb-md-15 bg-info" id="register">

      <!-- Shape -->
      <div class="shape shape-blur-3 text-white">
        <svg viewBox="0 0 1738 487" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M0 0h1420.92s713.43 457.505 0 485.868C707.502 514.231 0 0 0 0z" fill="url(#paint0_linear)"/><defs><linearGradient id="paint0_linear" x1="0" y1="0" x2="1049.98" y2="912.68" gradientUnits="userSpaceOnUse"><stop stop-color="currentColor" stop-opacity=".075"/><stop offset="1" stop-color="currentColor" stop-opacity="0"/></linearGradient></defs></svg>      </div>

      <!-- Content -->
      <div class="container">
        <div class="row justify-content-center">
          <div class="col-12 col-md-10 col-lg-8 text-center">

            <!-- Heading -->
            <h1 class="display-2 text-white">
              Join the community!
            </h1>

            <!-- Text -->
            <p class="lead text-white text-opacity-80 mb-6 mb-md-8">
              Learn for free, join the best tech learning community 
              for a <a class="text-white" href="https://www.reddit.com/r/sanfrancisco/comments/1bz90f6/why_are_coffee_shops_in_sf_so_expensive/" target="_blank">price of a pumpkin latte</a>.
            </p>

            <!-- Form -->
            <form class="d-flex align-items-center justify-content-center mb-7 mb-md-9">

              <!-- Label -->
              <span class="text-white text-opacity-80">
                Annual
              </span>

              <!-- Switch -->
              <div class="form-check form-check-dark form-switch mx-3">
                <input class="form-check-input" type="checkbox" id="billingSwitch" data-toggle="price" data-target=".price">
              </div>

              <!-- Label -->
              <span class="text-white text-opacity-80">
                Monthly
              </span>

            </form>

          </div>
        </div> <!-- / .row -->
      </div> <!-- / .container -->

    </section>

    <!-- SHAPE -->
    <div class="position-relative">
      <div class="shape shape-bottom shape-fluid-x text-light">
        <svg viewBox="0 0 2880 48" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M0 48h2880V0h-720C1442.5 52 720 0 720 0H0v48z" fill="currentColor"/></svg>      </div>
    </div>

    <!-- PRICING -->
    <section class="mt-n8 mt-md-n15">
      <div class="container">
        <div class="row gx-4">
          <div class="col-12 col-md-6">

            <!-- Card -->
            <div class="card shadow-lg mb-6 mb-md-1">
              <div class="card-body">

                <!-- Preheading -->
                <div class="text-center mb-3">
                  <span class="badge rounded-pill bg-primary-soft">
                    <span class="h6 text-uppercase">Newsletter</span>
                  </span>
                </div>

                <!-- Price -->
                <div class="d-flex justify-content-center">
                  <span class="h2 mb-0 mt-2">$</span>
                  <span class="price display-2 mb-0" data-annual="0" data-monthly="0">0</span>
                  <span class="h2 align-self-end mb-1">/mo</span>
                </div>

                <!-- Text -->
                <p class="text-center text-muted mb-5">
                </p>

              
                <div class="d-flex">
                  <div class="badge badge-rounded-circle bg-success-soft mt-1 me-4">
                    <i class="fe fe-check"></i>
                  </div>
                  <p>
                    Event notifications, weekly newsletter
                  </p>
                </div>
              
                <div class="d-flex">
                  <div class="badge badge-rounded-circle bg-success-soft mt-1 me-4">
                    <i class="fe fe-check"></i>
                  </div>
                  <p>
                    <b>Delayed access</b> to all content
                  </p>
                </div>
              
                <div class="d-flex">
                  <div class="badge badge-rounded-circle bg-success-soft mt-1 me-4">
                    <i class="fe fe-check"></i>
                  </div>
                  <p>
                    Immediate access to Keynotes & Panels
                  </p>
                </div>
              
              
              </div>
            </div>

            <!-- Card -->
            <div class="card shadow-lg mb-6 border border-success">
              <div class="card-body">

                <script>
    function gtag_report_conversion(url) {
      var callback = function () {
        if (typeof(url) != 'undefined') {
          window.location = url;
        }
      };
      gtag('event', 'conversion', {
          'send_to': 'AW-882275635/jLVTCPbt1N8CELPq2aQD',
          'event_callback': callback
      });
      return false;
    }
</script>

<!-- Form -->
<link rel="stylesheet" href="https://emailoctopus.com/bundles/emailoctopuslist/css/1.6/form.css">
<p class="emailoctopus-success-message text-success"></p>
<p class="emailoctopus-error-message text-danger"></p>
<form
    action="https://emailoctopus.com/lists/a3ba0cb5-7524-11eb-a3d0-06b4694bee2a/members/embedded/1.3/add"
    method="post"
    data-message-success="Thanks! Check your email for further directions!"
    data-message-missing-email-address="Your email address is required."
    data-message-invalid-email-address="Your email address looks incorrect, please try again."
    data-message-bot-submission-error="This doesn't look like a human submission."
    data-message-consent-required="Please check the checkbox to indicate your consent."
    data-message-invalid-parameters-error="This form has missing or invalid fields."
    data-message-unknown-error="Sorry, an unknown error has occurred. Please try again later."
    class="emailoctopus-form"
    data-sitekey="6LdYsmsUAAAAAPXVTt-ovRsPIJ_IVhvYBBhGvRV6"
>
<div class="form-floating emailoctopus-form-row">
    <input type="email" class="form-control form-control-flush" name="field_0" id="field_0" placeholder="Email" required>
    <label for="field_0">Email address</label>
</div>
<div class="form-floating emailoctopus-form-row">
    <input type="text" class="form-control form-control-flush" name="field_1" id="field_1" placeholder="First Name" required>
    <label for="field_1">First Name</label>
</div>
<div class="form-floating emailoctopus-form-row">
    <input type="text" class="form-control form-control-flush" name="field_2" id="field_2" placeholder="Last Name" required>
    <label for="field_2">Last Name</label>
</div>
<div class="form-floating emailoctopus-form-row">
    <input type="text" class="form-control form-control-flush" name="field_4" id="field_4" placeholder="Company" required>
    <label for="field_4">Company</label>
</div>
<div class="form-floating emailoctopus-form-row">
    <input type="text" class="form-control form-control-flush" name="field_5" id="field_5" placeholder="Job Title" required>
    <label for="field_5">Job Title</label>
</div>
<div class="form-floating emailoctopus-form-row">
    <input type="text" class="form-control form-control-flush" name="field_3" id="field_3" placeholder="Phone">
    <label for="field_3">Phone Number</label>
</div>
<div class="form-floating emailoctopus-form-row">
    <select type="text" class="form-control form-control-flush" name="field_7" id="country-source" required
    oninput="updateCountry()"
    >
    <!-- Country names and Country Name -->
    <option value="">Please select your country</option>
    <option value="Afghanistan">Afghanistan</option>
    <option value="Aland Islands">Aland Islands</option>
    <option value="Albania">Albania</option>
    <option value="Algeria">Algeria</option>
    <option value="American Samoa">American Samoa</option>
    <option value="Andorra">Andorra</option>
    <option value="Angola">Angola</option>
    <option value="Anguilla">Anguilla</option>
    <option value="Antarctica">Antarctica</option>
    <option value="Antigua and Barbuda">Antigua and Barbuda</option>
    <option value="Argentina">Argentina</option>
    <option value="Armenia">Armenia</option>
    <option value="Aruba">Aruba</option>
    <option value="Australia">Australia</option>
    <option value="Austria">Austria</option>
    <option value="Azerbaijan">Azerbaijan</option>
    <option value="Bahamas">Bahamas</option>
    <option value="Bahrain">Bahrain</option>
    <option value="Bangladesh">Bangladesh</option>
    <option value="Barbados">Barbados</option>
    <option value="Belarus">Belarus</option>
    <option value="Belgium">Belgium</option>
    <option value="Belize">Belize</option>
    <option value="Benin">Benin</option>
    <option value="Bermuda">Bermuda</option>
    <option value="Bhutan">Bhutan</option>
    <option value="Bolivia">Bolivia</option>
    <option value="Bonaire, Sint Eustatius and Saba">Bonaire, Sint Eustatius and Saba</option>
    <option value="Bosnia and Herzegovina">Bosnia and Herzegovina</option>
    <option value="Botswana">Botswana</option>
    <option value="Bouvet Island">Bouvet Island</option>
    <option value="Brazil">Brazil</option>
    <option value="British Indian Ocean Territory">British Indian Ocean Territory</option>
    <option value="Brunei Darussalam">Brunei Darussalam</option>
    <option value="Bulgaria">Bulgaria</option>
    <option value="Burkina Faso">Burkina Faso</option>
    <option value="Burundi">Burundi</option>
    <option value="Cambodia">Cambodia</option>
    <option value="Cameroon">Cameroon</option>
    <option value="Canada">Canada</option>
    <option value="Cape Verde">Cape Verde</option>
    <option value="Cayman Islands">Cayman Islands</option>
    <option value="Central African Republic">Central African Republic</option>
    <option value="Chad">Chad</option>
    <option value="Chile">Chile</option>
    <option value="China">China</option>
    <option value="Christmas Island">Christmas Island</option>
    <option value="Cocos (Keeling) Islands">Cocos (Keeling) Islands</option>
    <option value="Colombia">Colombia</option>
    <option value="Comoros">Comoros</option>
    <option value="Congo">Congo</option>
    <option value="Congo, Democratic Republic of the Congo">Congo, Democratic Republic of the Congo</option>
    <option value="Cook Islands">Cook Islands</option>
    <option value="Costa Rica">Costa Rica</option>
    <option value="Cote D'Ivoire">Cote D'Ivoire</option>
    <option value="Croatia">Croatia</option>
    <option value="Cuba">Cuba</option>
    <option value="Curacao">Curacao</option>
    <option value="Cyprus">Cyprus</option>
    <option value="Czech Republic">Czech Republic</option>
    <option value="Denmark">Denmark</option>
    <option value="Djibouti">Djibouti</option>
    <option value="Dominica">Dominica</option>
    <option value="Dominican Republic">Dominican Republic</option>
    <option value="Ecuador">Ecuador</option>
    <option value="Egypt">Egypt</option>
    <option value="El Salvador">El Salvador</option>
    <option value="Equatorial Guinea">Equatorial Guinea</option>
    <option value="Eritrea">Eritrea</option>
    <option value="Estonia">Estonia</option>
    <option value="Ethiopia">Ethiopia</option>
    <option value="Falkland Islands (Malvinas)">Falkland Islands (Malvinas)</option>
    <option value="Faroe Islands">Faroe Islands</option>
    <option value="Fiji">Fiji</option>
    <option value="Finland">Finland</option>
    <option value="France">France</option>
    <option value="French Guiana">French Guiana</option>
    <option value="French Polynesia">French Polynesia</option>
    <option value="French Southern Territories">French Southern Territories</option>
    <option value="Gabon">Gabon</option>
    <option value="Gambia">Gambia</option>
    <option value="Georgia">Georgia</option>
    <option value="Germany">Germany</option>
    <option value="Ghana">Ghana</option>
    <option value="Gibraltar">Gibraltar</option>
    <option value="Greece">Greece</option>
    <option value="Greenland">Greenland</option>
    <option value="Grenada">Grenada</option>
    <option value="Guadeloupe">Guadeloupe</option>
    <option value="Guam">Guam</option>
    <option value="Guatemala">Guatemala</option>
    <option value="Guernsey">Guernsey</option>
    <option value="Guinea">Guinea</option>
    <option value="Guinea-Bissau">Guinea-Bissau</option>
    <option value="Guyana">Guyana</option>
    <option value="Haiti">Haiti</option>
    <option value="Heard Island and Mcdonald Islands">Heard Island and Mcdonald Islands</option>
    <option value="Holy See (Vatican City State)">Holy See (Vatican City State)</option>
    <option value="Honduras">Honduras</option>
    <option value="Hong Kong">Hong Kong</option>
    <option value="Hungary">Hungary</option>
    <option value="Iceland">Iceland</option>
    <option value="India">India</option>
    <option value="Indonesia">Indonesia</option>
    <option value="Iran, Islamic Republic of">Iran, Islamic Republic of</option>
    <option value="Iraq">Iraq</option>
    <option value="Ireland">Ireland</option>
    <option value="Isle of Man">Isle of Man</option>
    <option value="Israel">Israel</option>
    <option value="Italy">Italy</option>
    <option value="Jamaica">Jamaica</option>
    <option value="Japan">Japan</option>
    <option value="Jersey">Jersey</option>
    <option value="Jordan">Jordan</option>
    <option value="Kazakhstan">Kazakhstan</option>
    <option value="Kenya">Kenya</option>
    <option value="Kiribati">Kiribati</option>
    <option value="Korea, Democratic People's Republic of">Korea, Democratic People's Republic of</option>
    <option value="Korea, Republic of">Korea, Republic of</option>
    <option value="Kosovo">Kosovo</option>
    <option value="Kuwait">Kuwait</option>
    <option value="Kyrgyzstan">Kyrgyzstan</option>
    <option value="Lao People's Democratic Republic">Lao People's Democratic Republic</option>
    <option value="Latvia">Latvia</option>
    <option value="Lebanon">Lebanon</option>
    <option value="Lesotho">Lesotho</option>
    <option value="Liberia">Liberia</option>
    <option value="Libyan Arab Jamahiriya">Libyan Arab Jamahiriya</option>
    <option value="Liechtenstein">Liechtenstein</option>
    <option value="Lithuania">Lithuania</option>
    <option value="Luxembourg">Luxembourg</option>
    <option value="Macao">Macao</option>
    <option value="Macedonia, the Former Yugoslav Republic of">Macedonia, the Former Yugoslav Republic of</option>
    <option value="Madagascar">Madagascar</option>
    <option value="Malawi">Malawi</option>
    <option value="Malaysia">Malaysia</option>
    <option value="Maldives">Maldives</option>
    <option value="Mali">Mali</option>
    <option value="Malta">Malta</option>
    <option value="Marshall Islands">Marshall Islands</option>
    <option value="Martinique">Martinique</option>
    <option value="Mauritania">Mauritania</option>
    <option value="Mauritius">Mauritius</option>
    <option value="Mayotte">Mayotte</option>
    <option value="Mexico">Mexico</option>
    <option value="Micronesia, Federated States of">Micronesia, Federated States of</option>
    <option value="Moldova, Republic of">Moldova, Republic of</option>
    <option value="Monaco">Monaco</option>
    <option value="Mongolia">Mongolia</option>
    <option value="Montenegro">Montenegro</option>
    <option value="Montserrat">Montserrat</option>
    <option value="Morocco">Morocco</option>
    <option value="Mozambique">Mozambique</option>
    <option value="Myanmar">Myanmar</option>
    <option value="Namibia">Namibia</option>
    <option value="Nauru">Nauru</option>
    <option value="Nepal">Nepal</option>
    <option value="Netherlands">Netherlands</option>
    <option value="Netherlands Antilles">Netherlands Antilles</option>
    <option value="New Caledonia">New Caledonia</option>
    <option value="New Zealand">New Zealand</option>
    <option value="Nicaragua">Nicaragua</option>
    <option value="Niger">Niger</option>
    <option value="Nigeria">Nigeria</option>
    <option value="Niue">Niue</option>
    <option value="Norfolk Island">Norfolk Island</option>
    <option value="Northern Mariana Islands">Northern Mariana Islands</option>
    <option value="Norway">Norway</option>
    <option value="Oman">Oman</option>
    <option value="Pakistan">Pakistan</option>
    <option value="Palau">Palau</option>
    <option value="Palestinian Territory, Occupied">Palestinian Territory, Occupied</option>
    <option value="Panama">Panama</option>
    <option value="Papua New Guinea">Papua New Guinea</option>
    <option value="Paraguay">Paraguay</option>
    <option value="Peru">Peru</option>
    <option value="Philippines">Philippines</option>
    <option value="Pitcairn">Pitcairn</option>
    <option value="Poland">Poland</option>
    <option value="Portugal">Portugal</option>
    <option value="Puerto Rico">Puerto Rico</option>
    <option value="Qatar">Qatar</option>
    <option value="Reunion">Reunion</option>
    <option value="Romania">Romania</option>
    <option value="Russian Federation">Russian Federation</option>
    <option value="Rwanda">Rwanda</option>
    <option value="Saint Barthelemy">Saint Barthelemy</option>
    <option value="Saint Helena">Saint Helena</option>
    <option value="Saint Kitts and Nevis">Saint Kitts and Nevis</option>
    <option value="Saint Lucia">Saint Lucia</option>
    <option value="Saint Martin">Saint Martin</option>
    <option value="Saint Pierre and Miquelon">Saint Pierre and Miquelon</option>
    <option value="Saint Vincent and the Grenadines">Saint Vincent and the Grenadines</option>
    <option value="Samoa">Samoa</option>
    <option value="San Marino">San Marino</option>
    <option value="Sao Tome and Principe">Sao Tome and Principe</option>
    <option value="Saudi Arabia">Saudi Arabia</option>
    <option value="Senegal">Senegal</option>
    <option value="Serbia">Serbia</option>
    <option value="Serbia and Montenegro">Serbia and Montenegro</option>
    <option value="Seychelles">Seychelles</option>
    <option value="Sierra Leone">Sierra Leone</option>
    <option value="Singapore">Singapore</option>
    <option value="Sint Maarten">Sint Maarten</option>
    <option value="Slovakia">Slovakia</option>
    <option value="Slovenia">Slovenia</option>
    <option value="Solomon Islands">Solomon Islands</option>
    <option value="Somalia">Somalia</option>
    <option value="South Africa">South Africa</option>
    <option value="South Georgia and the South Sandwich Islands">South Georgia and the South Sandwich Islands</option>
    <option value="South Sudan">South Sudan</option>
    <option value="Spain">Spain</option>
    <option value="Sri Lanka">Sri Lanka</option>
    <option value="Sudan">Sudan</option>
    <option value="Suriname">Suriname</option>
    <option value="Svalbard and Jan Mayen">Svalbard and Jan Mayen</option>
    <option value="Swaziland">Swaziland</option>
    <option value="Sweden">Sweden</option>
    <option value="Switzerland">Switzerland</option>
    <option value="Syrian Arab Republic">Syrian Arab Republic</option>
    <option value="Taiwan, Province of China">Taiwan, Province of China</option>
    <option value="Tajikistan">Tajikistan</option>
    <option value="Tanzania, United Republic of">Tanzania, United Republic of</option>
    <option value="Thailand">Thailand</option>
    <option value="Timor-Leste">Timor-Leste</option>
    <option value="Togo">Togo</option>
    <option value="Tokelau">Tokelau</option>
    <option value="Tonga">Tonga</option>
    <option value="Trinidad and Tobago">Trinidad and Tobago</option>
    <option value="Tunisia">Tunisia</option>
    <option value="Turkey">Turkey</option>
    <option value="Turkmenistan">Turkmenistan</option>
    <option value="Turks and Caicos Islands">Turks and Caicos Islands</option>
    <option value="Tuvalu">Tuvalu</option>
    <option value="Uganda">Uganda</option>
    <option value="Ukraine">Ukraine</option>
    <option value="United Arab Emirates">United Arab Emirates</option>
    <option value="United Kingdom">United Kingdom</option>
    <option value="United States">United States</option>
    <option value="United States Minor Outlying Islands">United States Minor Outlying Islands</option>
    <option value="Uruguay">Uruguay</option>
    <option value="Uzbekistan">Uzbekistan</option>
    <option value="Vanuatu">Vanuatu</option>
    <option value="Venezuela">Venezuela</option>
    <option value="Viet Nam">Viet Nam</option>
    <option value="Virgin Islands, British">Virgin Islands, British</option>
    <option value="Virgin Islands, U.s.">Virgin Islands, U.s.</option>
    <option value="Wallis and Futuna">Wallis and Futuna</option>
    <option value="Western Sahara">Western Sahara</option>
    <option value="Yemen">Yemen</option>
    <option value="Zambia">Zambia</option>
    <option value="Zimbabwe">Zimbabwe</option>
    </select>
    <label for="field_7">Country</label>
</div>
<input id="country-destination" name="field_7" type="hidden">
<input id="tz-country" name="field_8" type="hidden">

<input
    name="field_6"
    type="hidden"
    value="DevOps"
>

<div class="emailoctopus-form-row-consent">
    <input
    type="checkbox"
    id="consent"
    name="consent"
    >
    <label for="consent">
    I consent to the following terms:
    </label>
    <a href="https://www.conf42.com/terms-and-conditions.pdf" target="_blank">
    Terms and Conditions
    </a>
    &amp;
    <a href="./code-of-conduct" target="_blank">
    Code of Conduct
    </a>
</div>
<div
    aria-hidden="true"
    class="emailoctopus-form-row-hp"
>
    <input
    type="text"
    name="hpc4b27b6e-eb38-11e9-be00-06b4694bee2a"
    tabindex="-1"
    autocomplete="nope"
    >
</div>
<div class="mt-6 emailoctopus-form-row-subscribe">
    <input
    type="hidden"
    name="successRedirectUrl"
    >
    <button class="btn w-100 btn-success lift" type="submit" onclick="gtag_report_conversion(); rdt('track', 'SignUp');">
    Subscribe to free newsletter <i class="fe fe-arrow-right ms-3"></i>
    </button>
</div>
</form>

<!-- <script src="https://emailoctopus.com/bundles/emailoctopuslist/js/1.6/form-recaptcha.js"></script> -->
<script src="https://emailoctopus.com/bundles/emailoctopuslist/js/1.6/form-embed.js"></script>

              </div>
            </div>
          </div>
          <div class="col-12 col-md-6">

            <!-- Card -->
            <div class="card shadow-lg mb-6 mb-md-0">
              <div class="card-body">

                <!-- Preheading -->
                <div class="text-center mb-3">
                  <span class="badge rounded-pill bg-primary-soft">
                    <span class="h6 text-uppercase">Community</span>
                  </span>
                </div>

                <!-- Price -->
                <div class="d-flex justify-content-center">
                  <span class="h2 mb-0 mt-2">$</span>
                  <span class="price display-2 mb-0" data-annual="8.34" data-monthly="10">8.34</span>
                  <span class="h2 align-self-end mb-1">/mo</span>
                </div>

                <!-- Text -->
                <p class="text-center text-muted mb-5">
                </p>

                <div class="d-flex">
                  <div class="badge badge-rounded-circle bg-success-soft mt-1 me-4">
                    <i class="fe fe-check"></i>
                  </div>
                  <p>
                    Access to <a href="https://conf42.circle.so/">Circle community platform</a>
                  </p>
                </div>

                
                <div class="d-flex">
                  <div class="badge badge-rounded-circle bg-success-soft mt-1 me-4">
                    <i class="fe fe-check"></i>
                  </div>
                  <p>
                    <b>Immediate access</b> to all content
                  </p>
                </div>
                
                <div class="d-flex">
                  <div class="badge badge-rounded-circle bg-success-soft mt-1 me-4">
                    <i class="fe fe-check"></i>
                  </div>
                  <p>
                    <a href="https://conf42.circle.so/c/live-events/" target="_blank"><b>Live events!</b></a>
                  </p>
                </div>
                
                <div class="d-flex">
                  <div class="badge badge-rounded-circle bg-success-soft mt-1 me-4">
                    <i class="fe fe-check"></i>
                  </div>
                  <p>
                    <a href="https://conf42.circle.so/c/live-events/" target="_blank">Regular office hours, Q&As, CV reviews</a>
                  </p>
                </div>
                
                <div class="d-flex">
                  <div class="badge badge-rounded-circle bg-success-soft mt-1 me-4">
                    <i class="fe fe-check"></i>
                  </div>
                  <p>
                    Courses, quizes & certificates
                  </p>
                </div>
                
                <div class="d-flex">
                  <div class="badge badge-rounded-circle bg-success-soft mt-1 me-4">
                    <i class="fe fe-check"></i>
                  </div>
                  <p>
                    Community chats
                  </p>
                </div>
                

                <!-- Button -->
                <a href="https://conf42.circle.so/checkout/subscribe" class="btn w-100 btn-primary">
                  Join the community (7 day free trial)<i class="fe fe-arrow-right ms-3"></i>
                </a>

              </div>
            </div>

          </div>
        </div> <!-- / .row -->
      </div> <!-- / .container -->
    </section>

    <!-- SHAPE -->
    <div class="position-relative">
      <div class="shape shape-bottom shape-fluid-x svg-shim text-dark">
        <svg viewBox="0 0 2880 48" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M0 48h2880V0h-720C1442.5 52 720 0 720 0H0v48z" fill="currentColor"/></svg>      </div>
    </div>

    <!-- FOOTER -->
    <footer class="py-8 py-md-11 bg-dark">
      <div class="container">
        <div class="row">

          <div class="col-12 col-md-4 col-lg-3">
            <!-- Brand -->
            <img src="./assets/conf42/conf42_logo_white_small.png" alt="..." class="footer-brand img-fluid mb-2">
    
            <!-- Text -->
            <p class="text-gray-700 mb-2">
              Online tech events
            </p>
    
            <!-- Social -->
            <ul class="list-unstyled list-inline list-social mb-5">
              <li class="list-inline-item list-social-item me-3">
                <a href="https://www.linkedin.com/company/49110720/" class="text-decoration-none">
                  <img src="./assets/img/icons/social/linkedin.svg" class="list-social-icon" alt="...">
                </a>
              </li>
              <li class="list-inline-item list-social-item me-3">
                <a href="https://twitter.com/conf42com" class="text-decoration-none">
                  <img src="./assets/img/icons/social/twitter.svg" class="list-social-icon" alt="...">
                </a>
              </li>
            </ul>

            <!-- QR Code -->
            <img src="./assets/conf42/CONF42.QR.png" style="width: 100px;" class="mb-5 img-fluid" />
          </div>


          <div class="col-12 col-md-4 col-lg-3">
          
            <!-- Heading -->
            <h6 class="fw-bold text-uppercase text-gray-700">
              Events 2025
            </h6>
            <!-- List -->
            <ul class="list-unstyled text-muted mb-6 mb-md-8 mb-lg-0">
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/devops2025">
                  DevOps 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/python2025">
                  Python 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/ce2025">
                  Chaos Engineering 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/cloud2025">
                  Cloud Native 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/llms2025">
                  Large Language Models (LLMs) 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/golang2025">
                  Golang 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/sre2025">
                  Site Reliability Engineering (SRE) 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/ml2025">
                  Machine Learning 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/obs2025">
                  Observability 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/quantum2025">
                  Quantum Computing 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/rustlang2025">
                  Rustlang 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/platform2025">
                  Platform Engineering 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/mlops2025">
                  MLOps 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/im2025">
                  Incident Management 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/kubenative2025">
                  Kube Native 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/js2025">
                  JavaScript 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/prompt2025">
                  Prompt Engineering 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/robotics2025">
                  Robotics 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/devsecops2025">
                  DevSecOps 2025
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/iot2025">
                  Internet of Things (IoT) 2025
                </a>
              </li>
            
            </ul>
          
            <!-- Heading -->
            <h6 class="fw-bold text-uppercase text-gray-700">
              Events 2024
            </h6>
            <!-- List -->
            <ul class="list-unstyled text-muted mb-6 mb-md-8 mb-lg-0">
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/devops2024">
                  DevOps 2024
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/ce2024">
                  Chaos Engineering 2024
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/python2024">
                  Python 2024
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/cloud2024">
                  Cloud Native 2024
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/llms2024">
                  Large Language Models (LLMs) 2024
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/golang2024">
                  Golang 2024
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/sre2024">
                  Site Reliability Engineering (SRE) 2024
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/ml2024">
                  Machine Learning 2024
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/obs2024">
                  Observability 2024
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/quantum2024">
                  Quantum Computing 2024
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/rustlang2024">
                  Rustlang 2024
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/platform2024">
                  Platform Engineering 2024
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/kubenative2024">
                  Kube Native 2024
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/im2024">
                  Incident Management 2024
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/js2024">
                  JavaScript 2024
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/prompt2024">
                  Prompt Engineering 2024
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/devsecops2024">
                  DevSecOps 2024
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/iot2024">
                  Internet of Things (IoT) 2024
                </a>
              </li>
            
            </ul>
          
            <!-- Heading -->
            <h6 class="fw-bold text-uppercase text-gray-700">
              Events 2023
            </h6>
            <!-- List -->
            <ul class="list-unstyled text-muted mb-6 mb-md-8 mb-lg-0">
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/devops2023">
                  DevOps 2023
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/ce2023">
                  Chaos Engineering 2023
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/python2023">
                  Python 2023
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/cloud2023">
                  Cloud Native 2023
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/golang2023">
                  Golang 2023
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/sre2023">
                  Site Reliability Engineering 2023
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/ml2023">
                  Machine Learning 2023
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/obs2023">
                  Observability 2023
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/quantum2023">
                  Quantum Computing 2023
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/rustlang2023">
                  Rustlang 2023
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/platform2023">
                  Platform Engineering 2023
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/kubenative2023">
                  Kube Native 2023
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/im2023">
                  Incident Management 2023
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/js2023">
                  JavaScript 2023
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/devsecops2023">
                  DevSecOps 2023
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/iot2023">
                  Internet of Things (IoT) 2023
                </a>
              </li>
            
            </ul>
          
            <!-- Heading -->
            <h6 class="fw-bold text-uppercase text-gray-700">
              Events 2022
            </h6>
            <!-- List -->
            <ul class="list-unstyled text-muted mb-6 mb-md-8 mb-lg-0">
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/python2022">
                  Python 2022
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/mobile2022">
                  Mobile 2022
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/ce2022">
                  Chaos Engineering 2022
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/golang2022">
                  Golang 2022
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/cloud2022">
                  Cloud Native 2022
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/ml2022">
                  Machine Learning 2022
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/sre2022">
                  Site Reliability Engineering 2022
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/quantum2022">
                  Quantum Computing 2022
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/rustlang2022">
                  Rustlang 2022
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/im2022">
                  Incident Management 2022
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/kubenative2022">
                  Kube Native 2022
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/js2022">
                  JavaScript 2022
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/devsecops2022">
                  DevSecOps 2022
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/web2022">
                  Web 3.0 2022
                </a>
              </li>
            
            </ul>
          
            <!-- Heading -->
            <h6 class="fw-bold text-uppercase text-gray-700">
              Events 2021
            </h6>
            <!-- List -->
            <ul class="list-unstyled text-muted mb-6 mb-md-8 mb-lg-0">
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/ce2021">
                  Chaos Engineering 2021
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/enterprise2021">
                  Enterprise Software 2021
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/cloud2021">
                  Cloud Native 2021
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/python2021">
                  Python 2021
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/golang2021">
                  Golang 2021
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/ml2021">
                  Machine Learning 2021
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/sre2021">
                  Site Reliability Engineering 2021
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/js2021">
                  JavaScript 2021
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/devsecops2021">
                  DevSecOps 2021
                </a>
              </li>
            
            </ul>
          
            <!-- Heading -->
            <h6 class="fw-bold text-uppercase text-gray-700">
              Events 2020
            </h6>
            <!-- List -->
            <ul class="list-unstyled text-muted mb-6 mb-md-8 mb-lg-0">
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/ce2020">
                  Chaos Engineering 2020
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/oss2020">
                  Open Source Showcase 2020
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/sre2020">
                  Site Reliability Engineering 2020
                </a>
              </li>
            
              <li class="mb-3">
                <a class="text-reset" href="https://www.conf42.com/js2020">
                  JavaScript 2020
                </a>
              </li>
            
            </ul>
          
          </div>

          
          <div class="col-12 col-md-4 offset-md-4 col-lg-3 offset-lg-0">

            <!-- Heading -->
            <h6 class="fw-bold text-uppercase text-gray-700">
              Community
            </h6>
            <!-- List -->
            <ul class="list-unstyled text-muted mb-0">
              <li class="mb-3">
                <a href="./support" class="text-reset">
                  Support us
                </a>
              </li>
              <li class="mb-3">
                <a href="./speakers" class="text-reset">
                  Speakers
                </a>
              </li>
              <li class="mb-3">
                <a href="./hall-of-fame" class="text-reset">
                  Hall of fame
                </a>
              </li>
              <li class="mb-3">
                <a href="https://discord.gg/DnyHgrC7jC" class="text-reset" target="_blank">
                  Discord
                </a>
              </li>
              <li class="mb-3">
                <a href="./about" class="text-reset">
                  About the team
                </a>
              </li>
            </ul>

            <!-- Heading -->
            <h6 class="fw-bold text-uppercase text-gray-700">
              Sponsors
            </h6>
            <!-- List -->
            <ul class="list-unstyled text-muted mb-0">
              <li class="mb-3">
                <a href="./sponsor" class="text-reset" target="_blank">
                  Sponsorship
                </a>
              </li>
              <li class="mb-3">
                <a href="mailto:mark@conf42.com?subject=We would like to sponsor" class="text-reset" target="_blank">
                  Request the Prospectus
                </a>
              </li>
              <li class="mb-3">
                <a href="https://drive.google.com/drive/folders/1tT2lspLQgj3sdfxG9FwDVkBUt-TYSPGe?usp=sharing" class="text-reset" target="_blank">
                  Media kit
                </a>
              </li>
            </ul>
    
          </div>


          <div class="col-12 col-md-4 col-lg-3">
    
            <!-- Heading -->
            <h6 class="fw-bold text-uppercase text-gray-700">
              Legal
            </h6>
    
            <!-- List -->
            <ul class="list-unstyled text-muted mb-0">
              <li class="mb-3">
                <a href="./code-of-conduct" class="text-reset">
                  Code of Conduct
                </a>
              </li>
              <li class="mb-3">
                <a href="https://www.conf42.com/terms-and-conditions.pdf" class="text-reset" target="_blank">
                  Terms and Conditions
                </a>
              </li>
              <li class="mb-3">
                <a href="https://www.conf42.com/privacy-policy.pdf" class="text-reset" target="_blank">
                  Privacy policy
                </a>
              </li>
            </ul>
          </div>


        </div> <!-- / .row -->
      </div> <!-- / .container -->
    </footer>

    <!-- JAVASCRIPT -->
    <!-- Map JS -->
    <script src='https://api.mapbox.com/mapbox-gl-js/v0.53.0/mapbox-gl.js'></script>
    
    <!-- Vendor JS -->
    <script src="./assets/js/vendor.bundle.js"></script>
    
    <!-- Theme JS -->
    <script src="./assets/js/theme.bundle.js"></script>

    <!-- Various JS -->
    <script src="./assets/js/various.js"></script>

    <script src='https://cdn.jsdelivr.net/npm/@widgetbot/crate@3' async defer>
      new Crate({
          notifications: true,
          indicator: true,
          server: '814240231606714368', // Conf42.com
          channel: '814240231788249115' // #community
      })
    </script>
  </body>
</html>